Document:

<PAGE>

                                                                   EXHIBIT 10.65

                        GLOBAL MASTER RENTAL AGREEMENT

GLOBAL MASTER RENTAL AGREEMENT (the "Agreement") dated  May 4, 2000 by and
between COMDISCO, INC., acting on behalf of itself and its Affiliates
("Comdisco"), and SEQUENOM, INC., acting on behalf of itself and its Affiliates
("Customer").

Comdisco and its Affiliates are engaged in the rental of equipment in various
countries where Customer and its Affiliates may wish to rent such equipment.

To facilitate the transacting of rental operations between Comdisco or an
Affiliate of Comdisco and Customer or an Affiliate of the Customer on an ongoing
basis, Comdisco and the Customer wish to enter into the present Agreement which,
together with the Schedule under which each individual rental operation is
concluded, will establish the terms and conditions applicable to such rental
operation.

IN CONSIDERATION of the mutual agreements described below, the parties agree as
follows (all capitalized terms not otherwise defined in the body of this
Agreement are defined in Section 15.12):

1. Property Rented, Customer Liability, Conflict.
        Lessor rents to Lessee all of the Equipment described on each Schedule,
subject to the terms and conditions of this Agreement and such Schedule.  Each
such Schedule will be governed by all of the terms and conditions of this
Agreement and such additional terms and conditions as may be set forth in such
Schedule. Customer will, without notice,  be jointly and severally liable for
the due performance of the obligations of its Affiliates under all Schedules
executed hereunder, including, without limitation, all terms and conditions
negotiated by its Affiliates.  In the event of a conflict, the terms of a
Schedule prevail over this Agreement.

        The parties agree that each local transaction will only be validly
concluded if the relevant Schedule is executed by authorized signatories of
Lessor and Lessee involved in such transaction, and that any such Schedule may
also be supplemented or amended by special terms or conditions agreed upon by
Lessor or Lessee for the particular transaction.

2. Term.
        On the Commencement Date Lessee will be deemed to accept the Equipment,
will be bound to its Rent obligations for each item of Equipment and the term of
a Schedule will begin and continue through the Initial Term and thereafter until
terminated by either party upon prior written notice received during the Notice
Period.  No termination may be effective prior to the expiration of the Initial
Term.

3. Rent and Payments.
        Rent is due and payable in advance, in immediately available funds, in
the currency indicated on the Schedule, on the first day of each Rent Interval
to the payee and at the location specified in Lessor's invoice. The Interim Rent
is due and payable when invoiced. If any payment is not made when due, Lessee
will owe and pay interest at the Overdue Rate.

4. Selection and Warranty and Disclaimer of Warranties.
        4.1 Selection. Lessee acknowledges that it has selected the Equipment
and disclaims any reliance upon statements made by the Lessor.

        4.2 Warranty and Disclaimer of Warranties. Lessor warrants to Lessee
that, so long as Lessee is not in default, Lessor will not disturb Lessee's
quiet and peaceful possession, and unrestricted use of the Equipment. To the
extent permitted by the manufacturer, Lessor assigns to Lessee during the term
of the Schedule any manufacturer's warranties for the Equipment. LESSOR MAKES NO
OTHER WARRANTY, EXPRESS OR IMPLIED AS TO ANY MATTER WHATSOEVER, INCLUDING,
WITHOUT LIMITATION, THE MERCHANTABILITY OF THE EQUIPMENT OR ITS FITNESS FOR A
PARTICULAR PURPOSE. Lessor is not responsible for any liability, claim, loss,
damage or expense of any kind (including strict liability in tort) caused by the
Equipment except for any loss or damage caused by the negligent acts of Lessor.
In no event is Lessor responsible for special, incidental or consequential
damages.

5. Title and Assignment.

        5.1 Title. Lessee holds the Equipment subject and subordinate to the
rights of the Owner, Lessor, any Assignee and any Secured Party. Lessee
authorizes Lessor, as Lessee's agent to the extent relevant, to prepare, execute
and file in Lessee's name precautionary financing statements if applicable in
the relevant jurisdiction showing the interest of the Owner, Lessor, and any
Assignee or Secured Party in the Equipment, and
<PAGE>

to insert serial numbers in Schedules as appropriate. Except as provided in
Sections 5.2 and 7.2, Lessee will, at its expense, keep the Equipment free and
clear from any liens or encumbrances of any kind (except any caused by Lessor)
and will indemnify and hold Lessor, Owner, any Assignee and Secured Party
harmless from and against any loss caused by Lessee's failure to do so.

        5.2 Relocation. Upon prior written notice, Lessee may relocate Equipment
to any location within the country set forth in the respective Schedule provided
all additional costs arising from such relocation (including but not limited to
any administrative fees, additional duties, taxes and insurance coverage) are
reconciled and promptly paid by Lessee. No relocation will relieve Lessee from
any of its obligations under this Agreement and the relevant Schedule.

        5.3 Assignment by Lessor. The terms and conditions of each Schedule have
been fixed by Lessor in order to permit Lessor to sell and/or assign or transfer
its interest or grant a security interest in each Schedule and/or the Equipment
to a Secured Party or Assignee. In that event the term Lessor will include the
Assignee and any Secured Party. However, any assignment, sale, or other transfer
by Lessor will not relieve Lessor of its obligations to Lessee and will not
materially change Lessee's duties or materially increase the burdens or risks
imposed on Lessee. The Lessee consents to and will acknowledge such assignments
in a written notice given to Lessee. Lessee also agrees that:

        (a) The Secured Party will be entitled to exercise all of Lessor's
        rights, but will not be obligated to perform any of the obligations of
        Lessor. The Secured Party will not disturb Lessee's quiet and peaceful
        possession and unrestricted use of the Equipment so long as Lessee is
        not in default and the Secured Party continues to receive all Rent
        payable under the Schedule; and

        (b) Lessee will pay all Rent and all other amounts payable to the
        Secured Party, despite any defense or claim which it has against Lessor.
        Lessee reserves its right to have recourse directly against Lessor for
        any defense or claim; and

        (c) Subject to and without impairment of Lessee's leasehold rights in
        the Equipment, Lessee holds the Equipment for the Secured Party to the
        extent of the Secured Party's rights in that Equipment.

        5.4 Assignment of Liability. Customer hereby agrees that its
representations and obligations under this Agreement may be assigned by
Comdisco, without notice, to Lessor under any Schedule issued hereunder, and
further assigned by Lessor without notice to a Secured Party or Assignee.

6. Net Obligation and Taxes and Fees.
        6.1 Net Obligation. Each Schedule constitutes the Lessee's absolute and
unconditional obligation to pay Rent and is not subject to any abatement,
reduction, set-off, defense, counterclaim, interruption, deferment or recoupment
for any reason whatsoever. Subject to Section 6.2, if Lessee is required by law
or regulation to make any deduction or withholding, Lessee shall pay to Lessor
an amount sufficient to assure that Lessor receives a net amount equal to the
Rent.

        6.2 Taxes and Fees. Lessee will pay when due or reimburse Lessor for all
 taxes, duties or any other charges (together with any related interest or
penalties not arising from the negligence of Lessor) accrued for or arising out
of the term of each Schedule against Lessor, Lessee or the Equipment by any
governmental authority (except only taxes on the net income of Lessor)
including, but not limited to, any withholding tax on income, value-added,
turnover, stamp or recouping tax ("Additional Costs"). If required, Lessor will
file any property tax returns for the Equipment and pay all property taxes due.
Lessee will reimburse Lessor for property taxes within thirty (30) days of
receipt of an invoice.

        Lessee ensures that Lessor will receive a net amount equal to the full
amount of the scheduled Rent (at the times and in the amounts as set forth on
the Schedule) which it expects to receive without regard to any such amounts
being subject to Additional Costs.

        Lessor shall cooperate with Lessee in obtaining any clearances which
Lessee shall seek to obtain which will minimize Lessee's burden in regard to
Additional Costs.

7. Care, Use and Maintenance, Attachments and Reconfigurations and Inspection by
Lessor.

        7.1 Care, Use and Maintenance. Lessee will maintain the Equipment in
good operating order and appearance, protect the Equipment from deterioration,
other than normal wear and tear, and will not use the Equipment for any purpose
other than that for which it was designed. If commercially available, Lessee
will maintain in force a standard maintenance contract with the manufacturer of
the Equipment, or another party acceptable to Lessor, and upon request will
provide Lessor with a complete copy of that contract. With Lessor's prior
written consent, Lessee may have the Equipment maintained by a party other than
the manufacturer. Lessee agrees to pay any costs necessary for the manufacturer
to bring the Equipment to the equipment specifications as of the Commencement
Date, and to re-certify the Equipment as eligible for manufacturer's maintenance
by termination of the applicable Schedule whether by expiration or otherwise.
Lessee agrees to accept and install all routine engineering updates made
available by the manufacturer so as to insure the Equipment is at the current
release. The rental term will continue upon the same terms and conditions until
recertification has been obtained.

        7.2 Attachments and Reconfigurations. Upon Lessor's prior written
consent, Lessee may reconfigure and install Attachments on the Equipment. In the
event of such a Reconfiguration or Attachment, Lessee shall, upon the return of
the Equipment, at its expense, restore the Equipment to the original
configuration specified on the Schedule in accordance with the manufacturer's
specifications and in the same operating order, repair and appearance as when
installed (normal wear and tear excluded). If any parts are removed from the
Equipment during the Reconfiguration or Attachment, the restoration will
include, at Lessee's option, the installation of either the original removed
parts or Like Parts. Alternatively, with Lessor's prior written consent which
will not be unreasonably withheld, Lessee may return the Equipment with any
Attachment or upgrade.

        7.3 Inspection by Lessor. Upon request, Lessee, during reasonable
business hours and subject to Lessee's security requirements, will make the
Equipment and its related log and maintenance records available to Lessor for
inspection.

8. Representations and Warranties of Lessee.
        Customer and Lessee represent and warrant that for this Agreement and
each Schedule:

        (a) The execution, delivery and performance of the Lessee have been duly
        authorized by all necessary corporate action;

        (b) The individual executing was duly authorized to do so;

        (c) This Agreement and each Schedule constitute legal, valid and binding
        agreements of the Lessee enforceable in accordance with their terms; and

        (d) The Equipment is personal property and when subjected to use by the
        Lessee will not be or become fixtures under applicable law.
<PAGE>

9. Delivery and Return of Equipment.
        Lessee assumes the full expense of transportation of the Equipment to
its initial location, installation, deinstallation, and return to a location
(including without limitation the expense of in-transit insurance) all pursuant
to Lessor's instructions and manufacturer's specifications. Regarding
deinstallation, Lessee will assure that the Equipment is deinstalled by the
manufacturer in accordance with the manufacturer's recommended procedures and
any Environmental Law, and returned with a Verification of Decontamination in
the same operating order, repair, condition and appearance as when originally
installed (less normal wear and tear and depreciation) meeting all original
equipment manufacturer's specifications for continued manufacturer's
maintenance, and accompanied by all associated documents, manuals, maintenance
records for the duration of the Initial Term or any extension thereof, spare
parts and accessories. In connection with deinstallation, any Contaminant
removed from the Equipment will be removed and transported by a licensed waste
removal transporter. During the period subsequent to receipt of a notice under
Section 2, Lessor may demonstrate the Equipment's operation in place and Lessee
will supply any of its personnel as may reasonably be required to assist in the
demonstrations. With respect to Equipment located outside the continental United
States, Lessee agrees that if returned to United States, the Equipment will meet
all United States engineering specifications, including but not limited to
United States power standards.

10. Labeling.
        Upon request, Lessee will mark the Equipment indicating Lessor's
interest. Lessee will keep all Equipment free from any other marking or labeling
which might be interpreted as a claim of ownership.

11. Indemnity.
        Lessee will indemnify and hold Lessor, any Assignee and any Secured
Party harmless from and against any and all claims, costs, expenses, damages and
liabilities, including reasonable attorneys' fees, arising out of the ownership
(for strict liability in tort only), selection, possession, renting, operation,
control, use, maintenance, delivery, return or other disposition of the
Equipment. However, Lessee is not responsible to a party indemnified hereunder
for any claims, costs, expenses, damages and liabilities occasioned by the
negligent acts of such indemnified party. Lessee agrees to carry bodily injury
and property damage liability insurance during the term of the Agreement with
insurance providers acceptable to Lessor, in amounts and against risks
customarily insured against by the Lessee on equipment owned by it. Any amounts
received by Lessor under that insurance will be credited against Lessee's
obligations under this Section.

12. Risk of Loss.
        Effective upon delivery and until the Equipment is returned, Lessee
relieves Lessor of responsibility for all risks of physical damage to or loss or
destruction of the Equipment.  Lessee will carry casualty insurance for each
item of Equipment in an amount not less than the Casualty Value.  All policies
for such insurance must be with insurance providers acceptable to Lessor and
will name the Lessor and any Secured Party as additional insured and as loss
payee, and will provide for at least thirty (30) days prior written notice to
the Lessor of cancellation or expiration.  The Lessee will furnish appropriate
evidence of such insurance.  Lessee shall promptly repair any damaged item of
Equipment unless such Equipment has suffered a Casualty Loss.  Within fifteen
(15) days of a Casualty Loss, Lessee will provide written notice of that loss to
Lessor and Lessee will, at Lessor's option, either (a) replace the item of
Equipment with Like Equipment and marketable title to the Like Equipment will
automatically vest in Lessor, or (b) pay the Casualty Value and after that
payment and the payment of all other amounts due and owing, Lessee's obligation
to pay further Rents for the item of Equipment will cease.

13. Default, Remedies and Mitigation.

        13.1 Default. The occurrence of any one or more of the following Events
of Default by Customer or by Lessee constitutes a default under this Agreement
or any Schedule entered into hereunder.

        (a) Failure to pay Rent or other amounts payable by Customer or Lessee
        when due if that failure continues for ten (10) days after written
        notice; or
<PAGE>

        (b) Failure to perform any other term or condition of this Agreement or
        the Schedule or the material inaccuracy of any representation or
        warranty made by Customer or Lessee in this Agreement or the Schedule or
        in any document or certificate furnished to the Lessor hereunder if that
        failure or inaccuracy continues for fifteen (15) days after written
        notice; or

        (c) An assignment for the benefit of its creditors, the failure to pay
        its debts when due, the insolvency of Lessee, the filing by or the
        filing against Customer or Lessee of any petition under any bankruptcy
        or insolvency law or for the appointment of a trustee or other officer
        with similar powers, the adjudication of Customer or Lessee as
        insolvent, the liquidation of Customer or Lessee, or the taking of any
        action for the purpose of the foregoing; or

        13.2 Remedies. Upon the occurrence of any of the above Events of
Default, Lessor, at its option, may, as to Customer or Lessee:

        (a) enforce performance of the provisions of the applicable Schedule by
        appropriate court action in law or in equity;

        (b) recover any damages and or expenses, including Default Costs;

        (c) with notice and demand, recover all sums due and accelerate and
        recover the present value of the remaining payments stream of all Rent
        due under the defaulted Schedule (discounted at the same rate of
        interest at which such defaulted Schedule was discounted with a Secured
        Party plus any prepayment fees charged to Lessor by the Secured Party
        or, if there is no Secured Party, then discounted at the then prevailing
        interbank offering rate for the currency specified in the Schedule less
        2%) together with all Rent and other amounts currently due as liquidated
        damages and not as a penalty;

        (d) with notice and process of law and in compliance with Lessee's
        security requirements, Lessor may enter on Lessee's premises to remove
        and repossess the Equipment without being liable to Lessee for damages
        due to the repossession, except those resulting from Lessor's, its
        assignees', agents' or representatives' negligence; and

        (e) pursue any other remedy permitted by law or equity.

        The above remedies, in Lessor's discretion and to the extent permitted
by law, are cumulative and may be exercised successively or concurrently.

        13.3 Mitigation. Upon return of the Equipment pursuant to the terms of
Section 13.2, Lessor will use its best efforts in accordance with its normal
business procedures (and without obligation to give any priority to such
Equipment) to mitigate Lessor's damages as described below. EXCEPT AS SET FORTH
IN THIS SECTION, LESSEE HEREBY WAIVES ANY RIGHTS NOW OR HEREAFTER CONFERRED BY
STATUTE OR OTHERWISE WHICH MAY REQUIRE LESSOR TO MITIGATE ITS DAMAGES OR MODIFY
ANY OF LESSOR'S RIGHTS OR REMEDIES STATED HEREIN. Lessor may sell, rents or
otherwise dispose of all or any part of the Equipment at a public or private
sale for cash or credit with the privilege of purchasing the Equipment. The
proceeds from any sale, rental or other disposition of the Equipment are defined
as either:

        (a) if sold or otherwise disposed of, the cash proceeds less the Fair
        Market Value of the Equipment at the expiration of the Initial Term less
        the Default Costs; or

        (b) if rented, the present value (discounted at three points over the
        prevailing interbank offering rate at the time of the mitigation) of the
        Rent for a term not to exceed the Initial Term, less the Default Costs.

        Any proceeds will be applied against liquidated damages and any other
sums due to Lessor from Lessee. However, Customer and Lessee are liable to
Lessor for, and Lessor may recover, the amount by which the proceeds are less
than the liquidated damages and other sums due to Lessor from Lessee.

14. Environmental Conditions.

        14.1 Indemnification. Lessee shall fully and promptly pay, perform,
discharge, defend, indemnify and hold harmless Comdisco, Lessor and its
Affiliates, successors and assigns, directors, officers, employees and agents
from and against any Environmental Claim or Environmental Loss.

        14.2 Lessee Cooperation. In the event of an Environmental Claim, Lessee
shall, upon request, immediately provide Lessor with copies of all
correspondence reports, notices, orders, findings, declarations and other
materials pertinent to the Lessee's compliance with and requirements of any
Environmental Law.
        14.3 Lessee Insurance.  The Lessee shall name Lessor as an additional
insured on its environmental liability insurance policy, if carried.

15. Additional Provisions.

        15.1 Entire Agreement. This Agreement and associated Schedules supersede
all other oral or written agreements or understandings between the parties
concerning the Equipment including, for example, purchase orders. ANY AMENDMENT
OF THIS Agreement OR A SCHEDULE, MAY ONLY BE ACCOMPLISHED BY A WRITING SIGNED BY
THE PARTIES.

        15.2 No Waiver. No action taken by Lessor or Lessee shall be deemed to
constitute a waiver of compliance with any representation, warranty or covenant
contained in this Agreement or a Schedule. The waiver by Lessor or Lessee of a
breach of any provision of this Agreement or a Schedule will not operate or be
construed as a waiver of any subsequent breach.

        15.3 Binding Nature. Each Schedule is binding upon, and inures to the
benefit of Lessor and its assigns. LESSEE MAY NOT ASSIGN ITS RIGHTS OR
OBLIGATIONS.

        15.4 Survival of Obligations. All agreements, obligations including, but
not limited to those arising under Sections 6.2 and 11, representations and
warranties contained in this Agreement, any Schedule or in any document
delivered in connection with those agreements are for the benefit of Lessor and
any Assignee or Secured Party and survive the execution, delivery, expiration or
termination of this Agreement.

        15.5 Notices. Any notice, request or other communication to either party
by the other will be given in writing and deemed received upon the earlier of
actual receipt or three days after mailing if mailed postage prepaid by airmail
to Lessor (to the attention of "Agreement Administrator") or Lessee, at the
address set out in the Schedule or, two days after it is sent by courier or
facsimile transmission if receipt is verified by the receiving party.

        15.6 Applicable Law. This Agreement shall be governed and construed for
all purposes in accordance with the law agreed upon in the applicable Schedule
by Lessor and Lessee. Comdisco and Customer hereby consent to such law. Customer
hereby consents to the jurisdiction of the court agreed upon in the applicable
Schedule.

        15.7 Severability. If any one or more of the provisions of this
Agreement or any Schedule is for any reason held invalid, illegal or
unenforceable, the remaining provisions of this Agreement and any such Schedule
will be unimpaired, and the invalid, illegal or unenforceable provision replaced
by a mutually acceptable valid, legal and enforceable provision that is closest
to the original intention of the parties.

        15.8 Counterparts. This Agreement and any Schedule may be executed in
any number of counterparts, each of which will be deemed an original, but all
such counterparts together constitute one and the same instrument. If Lessor
grants a security interest in all or any part of a Schedule, the Equipment or
sums payable thereunder, only that counterpart Schedule marked "Secured Party's
Original" can transfer Lessor's rights and all other counterparts will be marked
"Duplicate".

        15.9 Licensed Products. Lessee shall obtain no title to Licensed
Products which will at all times remain the property of the owner of the
Licensed Products. A license from the owner may be required and it is Lessee's
responsibility to obtain any required license before the use of the Licensed
<PAGE>

Products. Lessee agrees to treat the Licensed Products as confidential
information of the owner, to observe all copyright restrictions, and not to
reproduce or sell the Licensed Products.

        15.10 Additional Documents. Customer and Lessee will, upon execution of
this Agreement and as may be requested thereafter, provide Lessor and/or
Comdisco with a secretary's certificate of incumbency and authority and any
other documents reasonably requested by Lessor and/or Comdisco. Lessee will
furnish, upon request, quarterly and audited financial statements for the most
recent period.

        15.11 Electronic Communications. Each of the parties may communicate
with the other by electronic means under mutually agreeable terms.

        15.12 Definitions.

Adverse Environmental Condition - means (i) the existence or the continuation of
the existence, of an Environmental Emission (including, without limitation, a
sudden or non-sudden accidental or non-accidental Environmental Emission), of or
exposure to, any substance, chemical, material, pollutant, contaminant, odor or
audible noise or other release or emission in, into or onto the environment
(including without limitation, the air, ground, water or any surface) at, in,
by, from or related to any Equipment, (ii) the environmental aspect of the
transportation, storage, treatment or disposal of materials in connection with
the operation of any Equipment, or (iii) the violation, or alleged violation of
any statutes, ordinances, orders, rules, regulations, permits or licenses of, by
or from any governmental authority, agency or court relating to environmental
matters connected with any Equipment.

Affiliate - means as to Comdisco or Customer those enterprises which Comdisco or
Customer own or otherwise control directly or indirectly including, without
limitation, those listed on Exhibits A and B.

Assignee - means an entity to whom Lessor has sold or assigned its rights as
Owner and Lessor of Equipment.

Attachment - means any accessory, equipment or device and the installation
thereof that does not impair the original function or use of the Equipment and
is capable of being removed without causing material damage to the Equipment and
is not an accession to the Equipment.

Casualty Loss - means the irreparable loss or destruction of Equipment.

Casualty Value  - means an amount equal to the present value of the aggregate
Rent remaining for the balance of the Initial Term, plus the present value of
the Fair Market Value (determined as of the expiration of the Initial Term) of
Like Equipment discounted at the lesser of (x) the then prevailing interbank
offering rate less 2% or (y) the Secured Party interest rate, if any.

Commencement Certificate - means the Lessor provided certificate which must be
signed by Lessee within ten days of the Commencement Date as requested by
Lessor.

Commencement Date - is defined in each Schedule.

Contaminant - means those substances which are regulated by or from the basis of
liability under any Environmental Law, including without limitation, asbestos,
polychlorinated biphenyls ("PCB"), and radioactive substances, or other material
or substance which has in the past or could in the future constitute a healthy,
safety or environmental hazard to any person, property or natural resources.

Customer - means the enterprise other than Comdisco executing this Agreement on
behalf of itself and its Affiliates.

Default Costs - means reasonable attorney's fees and remarketing costs resulting
from a Lessee default or Lessor's enforcement of its remedies.

Environmental Claim - means any accusation, allegation, notice of violation,
claim, demand, abatement or other order or direction (conditional or otherwise)
by a governmental authority or any Person for personal injury (including
sickness, disease, or death), tangible or intangible property damage, damage to
the environment or natural resources, nuisance, pollution, contamination or
other adverse effects on the environment, or for fines, penalties or
restrictions, resulting from or based upon any Adverse Environmental Condition.

Environmental Emission - means any actual or threatened release, spill,
omission, leaking, pumping, injection, deposition, disposal, discharge,
dispersal, leaching or migration into the indoor or outdoor environment, or into
or out of any of the Equipment including, without limitation, the movement of
any Contaminant or other substance through or in the air, soil, surface water,
groundwater or property.

Environmental Law - means any federal, foreign, state or local law, rule or
regulation pertaining to the protection of the environment applicable to the
Equipment in the country of installation.

Environmental Loss - means any loss, cost, damage, liability, deficiency, fine,
penalty or expense (including, without limitation, reasonable attorney's fees,
engineering and other professional or expert fees), investigation, removal,
cleanup and remedial costs (voluntarily or involuntarily incurred) and damages
to, loss of the use of or decrease in value of the Equipment arising out of or
related to any Adverse Environmental Condition.

Equipment - means the property described on a Schedule and any replacement for
that property required or permitted by this Agreement or a Schedule but not
including any Attachment.

Event of Default - means the events described in Subsection 13.1.

Fair Market Value - means the aggregate amount which would be obtainable in an
arm's-length transaction between an informed and willing buyer/user purchasing
the Equipment in place for its originally intended use and an informed and
willing seller under no compulsion to sell.

Initial Term - means the period of time beginning on the first day of the first
full Rent Interval following the Commencement Date for all items of Equipment
and continuing for the number of Rent Intervals indicated on a Schedule.

Installation Date - means the day on which Equipment is installed and accepted
by Lessee in accordance with Lessee's or Lessor's equipment purchase
documentation.

Interbank Offering Rates - means short term rates used within a particular
country by banks lending money amongst themselves.

Interim Rent - means the pro-rata portion of Rent due for the period from the
Commencement Date through but not including the first day of the first full Rent
Interval included in the Initial Term.

Lessee - means with respect to any Schedule, the enterprise executing the
Schedule as Lessee, either Customer or an Affiliate of Customer.

Lessor - means with respect to any Schedule, the enterprise executing the
Schedule as Lessor, either Comdisco, Inc. or an Affiliate of Comdisco, Inc.

Licensed Products - means any software or other licensed products attached to
the Equipment.

Like Equipment - means replacement Equipment which is lien free and of the same
model, type, configuration and manufacture as Equipment.

Like Part - means a substituted part which is lien free and of the same
manufacturer and part number as the removed part, and which when installed on
the Equipment will be eligible for maintenance coverage with the manufacturer of
the Equipment.

Notice Period  - means the time period described in a Schedule during which
Lessee may give Lessor notice of the termination of the term of that Schedule.

Overdue Rate - means the lesser of 3% per year above the then prevailing
interbank offering rate or the maximum rate permitted by the law of the country
where the Equipment is located.

Owner - means the legal owner of the Equipment.

Person - means any individual, partnership, corporation, trust, unincorporated
organization, government or department or agency thereof and any other entity.
<PAGE>

Reconfiguration - means any change to Equipment that would upgrade or downgrade
the performance capabilities of the Equipment in any way.

Rent - means the rent, including Interim Rent, Lessee will pay for each item of
Equipment expressed in a Schedule either as a specific amount or an amount equal
to the amount which Lessor pays for an item of Equipment multiplied by a rental
rate factor plus all other amounts due to Lessor under this Agreement or a
Schedule.

Rent Interval - means a full calendar month or quarter as indicated on a
Schedule.

Schedule - means an Equipment Schedule, substantially in the form attached to
Exhibit C hereto or as may be added by agreement of Comdisco and Customer from
time to time, which incorporates all of the terms and conditions of this
Agreement and, for purposes of Section 15.8, its associated Commencement
Certificate(s).

Secured Party - means an entity to whom Lessor has granted a security interest
in a Schedule and related Equipment for the purpose of securing a loan.

Verification of Decontamination - means a letter from the party performing the
decontamination, stating that such party is licensed by OSHA or the appropriate
officials and that the actual decontamination was completed both in accordance
with manufacturer's specifications and procedures, and any governmental permit
required for the operation of the equipment and the disposal of any hazardous
material in connection therewith.

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement on or
as of the day and year first above written.

SEQUENOM, INC.                           COMDISCO, INC.,
as Customer                              as Lessor

By: /s/ STEPHEN ZANIBONI             By: /s/ DOUG BERMAN
   ----------------------------         ----------------------------

Title:    CFO                        Title: AVP
      -------------------------            -------------------------

Rev.5/99
GRMA:CEG
<PAGE>

                                   EXHIBIT A
                                   ---------

    To the Global Master Rental Agreement dated as of May 4, 2000, between
          Comdisco, Inc. ("Comdisco") and Sequenom, Inc. ("Customer")

                         AFFILIATES OF COMDISCO, INC.

<TABLE>
<CAPTION>
<S>                                        <C>
Comdisco Asia Pte Ltd                      Comdisco Ireland Limited
9, Temasek Boulevard                       30 Herbert Street
#09-01, Suntec Tower 2                     Dublin 2, Ireland
Singapore 038989
                                           Comdisco Japan, a branch of Comdisco
Comdisco Australia Pty Ltd                 GmbH & Co. Leasing and Finance KG
(CAN 002 997-453)                          Nomura Fudosan Building 11F
Level 18, 111 Pacific Highway              1-8-15 Azuchi-Machi
North Sydney, NSW 2060, Australia          J-Chuo-Ku, Osaka 541-0052
                                           (Japan)

                                           Comdisco de Mexico, S.A. de C.V.
Comdisco Canada Ltd.                       C/o Gardere & Wynne, Arena, Arce, Robles, Yarza, S.C.
Royal Bank Plaza, North Tower              Rio Panuco No. 7
200 Bay Street, Suite 2075                 Col. Cuauhtemoc
P.O. Box 131                               06500 Mexico, D.F.
CDN-Toronto, Ontario M5J 2J3               (Mexico)
(Canada)
                                           Comdisco Nederland B.V.
                                           Planetenbaan 15, Postbus 1681
                                           NL-3606 AK Maarssen
                                           (The Netherlands)
Comdisco Global Inc.
c/o Truman Bodden & Company                Comdisco New Zealand
P.O. Box 866                               Level 16, ASB Bank Centre
Anderson Square Building                   Cnr Albert and Wellesley Streets
Grand Cayman, British West Indies          Auckland, New Zealand

                                           Comdisco Trade, Inc. (Taiwan Branch)
                                           14F-06 Empire Commercial Building
                                           No. 295 Kuang-Fu Road Section 2
                                           Hsinchu, Taiwan
                                           (Republic of China)
</TABLE>

<PAGE>

                                   EXHIBIT B
                                   ---------

    To the Global Master Rental Agreement dated as of May 4, 2000, between
          Comdisco, Inc. ("Comdisco") and Sequenom, Inc. ("Customer")

                            AFFILIATES OF CUSTOMER

Sequenom GmbH
<PAGE>

                                   EXHIBIT C
                                   ---------

    To the Global Master Rental Agreement dated as of May 4, 2000, between
          Comdisco, Inc. ("Comdisco") and Sequenom, Inc. ("Customer")

      Effective as of the date of the Agreement, Comdisco and Customer hereby
    agree, pursuant to Subsection 1.2, "Equipment Schedules" of the Agreement
                                        -------------------
    that Equipment Schedules substantially in the forms attached hereto and
    identified by country name shall be used in the countries listed below which
    match the country name on the attached Equipment Schedules.

                   Australia             Mexico
                   **Austria          Netherlands
                   **Belgium             New Zealand
                   Canada                **Norway
                   **Czech Republic      Puerto Rico
                   **Denmark             Singapore
                   **Finland          **Spain
                   **France              **Sweden
                   **Germany             **Switzerland
                   Hong Kong             Taiwan
                   **Ireland             ** United Kingdom
                   **Italy               United States
                   Japan

                                          Initialled:    Comdisco ______________

                                                         Customer ______________

    **Leases will be written with Comdisco Nederland B.V., as Lessor
<PAGE>

                    ADDENDUM NO. 1 DATED AS OF MAY 4, 2000
                     TO THE GLOBAL MASTER RENTAL AGREEMENT
                   DATED AS OF MAY 4, 2000 (THE "AGREEMENT")
                      BETWEEN SEQUENOM, INC. ("CUSTOMER")
          AND COMDISCO LABORATORY AND SCIENTIFIC GROUP, A DIVISION OF
                           COMDISCO, INC. ("LESSOR")

The terms and conditions of this Addendum shall be incorporated into the
Agreement and supersedes the Agreement to the extent expressly provided herein.
Each capitalized terms used herein and not otherwise defined shall have the same
meaning attributed to it in the Agreement.

A.  The terms and conditions of the following sections of the Agreement are
hereby modified:

1.      SECTION 13.3, MITIGATION
        ------------------------

        Revise the second sentence to read as follows: "EXCEPT AS SET FORTH IN
        THIS SECTION, EACH PARTY HEREBY WAIVES ANY RIGHTS NOW OR HEREAFTER
        CONFERRED BY STATUTE OR OTHERWISE WHICH MAY REQUIRE LESSOR TO MITIGATE
        ITS DAMAGES ORMODIFY ANY OF LESSOR'S OR LESSEE'S RIGHTS OR REMEDIES
        STATED HEREIN."

2.      SECTION 15.12, DEFINITIONS
        --------------------------

        Under the definition of "Contaminant", line 2, delete the word
        "from" and insert the word "form".

IN WITNESS WHEREOF, the parties have caused this Addendum to be executed by
their authorized representatives as of the date and year set forth below.

ACCEPTED AND AGREED TO:

Sequenom, Inc.                              Comdisco,
Inc.

By: /s/ STEPHEN ZANIBONI                    By: /s/ DOUG BERMAN
   --------------------------------            -------------------------------

Printed Name: Stephen Zaniboni              Printed Name: Doug Berman
              ---------------------                       --------------------

Title: CFO                                  Title: AVP
       ----------------------------               ----------------------------

Date:                                       Date: 6/2/2000
     ------------------------------               ----------------------------
<PAGE>

                                AMENDMENT NO. 2
                                       TO
                         GLOBAL MASTER RENTAL AGREEMENT
                        DATED MAY 4, 2000 (the "Lease")
                                 BY AND BETWEEN
                           SEQUENOM, INC. ("Lessee")
                                      AND
                   COMDISCO LABORATORY AND SCIENTIFIC GROUP,
                    A DIVISION OF COMDISCO, INC. ("Lessor")

WHEREAS, Lessor and Lessee desire to enter into the Lease; and

WHEREAS, Lessor and Lessee desire to amend certain provisions of the Lease as
hereafter provided; and

WHEREAS, the Amendment shall be deemed to have been entered into
contemporaneously with and integrated into the terms and conditions of the
Lease.

NOW THEREFORE, for good and valuable consideration, Lessor and Lessee hereby
agree to amend the Lease as follows:

  1.  Lessee agrees to maintain a financial status of all of the following
during the term of the Lease and any extension or renewal thereof:

  a.  Tangible net worth of not less than $15,000,000.00;

  b.  Cash or equivalents of not less than $15,000,000.00;

  2.  In addition, Lessee agrees to provide Lessor with quarterly financial
statements within forty-five (45) days after the end of each fiscal quarter and
audited annual financial statements within one hundred twenty (120) days of the
end of each fiscal year.

  3.  Failure of Lessee to maintain any one of the above at any time during the
Lease term and any extension or renewal thereof or the failure to make any
payment due under the Lease is an Event of Default under the Lease which Lessee
must, within ten (10) days, provide a Letter of Credit from a bank acceptable to
Lessor for one hundred percent (100%) of all rent then due or to become due
under the lease as of the date of the default.  Along with the Letter of Credit,
Lessee shall also execute a Letter of Credit Agreement with Lessor.  The Letter
of Credit and Letter of Credit Agreement shall be in a form identical to
Exhibits A & B attached and incorporated herein.

  4.  Lessor shall also be entitled to any or all remedies or actions in the
event of default, as provided in the Lease, and this Amendment shall not be
construed to limit Lessor's rights in any way.

Except as set out herein, Lessor and Lessee hereby agree that the terms and
conditions of the Lease shall remain in full force and effect as entered into by
the parties on or prior to the date hereof.

                                             COMDISCO LABORATORY AND  SCIENTIFIC
SEQUENOM, INC.                               GROUP, a division of
as Lessee                                    COMDISCO, INC.
                                             as Lessor

By: /s/ STEPHEN ZANIBONI                     By: /s/ DOUG BERMAN
   -------------------------                    ----------------------------

Title: CFO                                   Title: AVP
       ---------------------                       -------------------------

Date:  5/25/2000                             Date:  6/2/2000
      ----------------------                      --------------------------
<PAGE>

                                   EXHIBIT A

                              (On Bank Letterhead)

(DATE)

BENEFICIARY:
Comdisco Laboratory and Scientific Group,
a division of Comdisco, Inc., or Transferee
6111 N. River Road
Rosemont, IL 60018

Gentlemen:

We hereby establish our Irrevocable Standby Letter of Credit No. ______ in your
favor for account of Sequenom, Inc., for a sum not to exceed  AND /100 DOLLARS
($) available by your draft drawn at sight on us.

Draft must be accompanied by:  Your statement signed by an officer  of Comdisco
Laboratory and Scientific Group, a division of Comdisco, Inc. certifying that
Sequenom ,Inc. has defaulted under that certain Global Master Rental Agreement
dated May 4, 2000 between Sequenom, Inc. and Comdisco Laboratory and Scientific
Group, a division of Comdisco, Inc., and the original of this Letter of Credit.

This Letter of Credit expires __________. All drafts drawn hereunder must be
present for payment at our office at ___________________ on or before that date.

It is a condition of this Irrevocable Standby Letter of Credit that it shall be
deemed automatically extended without amendment for one (1) year from the
present or any future expiration date hereof but not beyond end of lease term.
Should we elect not to renew this Standby Letter of Credit, we shall notify you
of such election 45 days prior to any such date.  All notices shall be in
writing, sent by certified mail, return receipt requested and addressed to you
at the above address, ATTENTION:   Credit Manager.  Notwithstanding receipt by
you of such notice, you may draw hereby by means of your draft on us at sight
accompanied by the documents required herein, until such expiration date.

This Letter of Credit may be transferred by you at any time and such transfer
shall be deemed effective and binding on us upon receipt of written notice of
such transfer from you when accompanied by the original of this Letter of
Credit.

We hereby agree that drafts drawn strictly in compliance with the terms of this
credit and any amendments thereto shall meet with due honor upon presentation at
our office at.

                                                    ___________________
                                                    Title
<PAGE>

                                   EXHIBIT B

                                LETTER OF CREDIT
                                   AGREEMENT

Stand-by Letter of Credit Agreement dated _____________, by and between
Sequenom, Inc. ("Lessee") located at  and Comdisco Laboratory and Scientific
Group, a division of Comdisco, Inc. ("Lessor") with offices at 6111 N. River
Road, Rosemont, IL  60018.

WHEREAS, Lessee has requested that Lessor lease various equipment, as further
described in the Lease (the "Equipment"), to Lessee; and

WHEREAS, Lessor has agreed to lease the Equipment to Lessee upon the condition
that an Irrevocable Stand-by Letter of Credit shall be outstanding for the full
term of the Master Lease Agreement to additionally secure Lessee's performance
under the Lease.

NOW THEREFORE, in consideration of and as an inducement to Lessor to lease the
Equipment to Lessee, the parties hereto agree as follows:

     1.  Lessee and Lessor have entered or shall enter into a Master Lease
Agreement and one or more Schedules thereunder for leasing the Equipment,
(together the "Lease"), all of which shall be covered by the terms of this
Agreement.

     2.  Concurrently with the execution for this Agreement, Lessee shall cause
to be delivered to Lessor in the form attached hereto as Exhibit A, an
Irrevocable Stand-by Letter of Credit issued by a bank acceptable to Lessor,
which Letter of Credit shall be in the amount of AND /100 dollars ($) ("Letter
of Credit") and shall be outstanding until __________, with annual renewals
until end of lease term.

     3.  Receipt by Lessor of notice that the Letter of Credit will not be
renewed on any expiration date, as provided therein, shall constitute a material
default by Lessee under the terms and conditions of the Lease. Lessor shall then
have the right to draw upon the Letter of Credit up to its full amount and to
apply the proceeds as set out in paragraph 4, below, unless at least thirty (30)
days prior to said expiration date Lessee replaces the Letter of Credit with a
Letter of Credit which has been issued by a bank acceptable to Lessor and has
the same terms and conditions as the replaced Letter of Credit.

     4.  Upon the occurrence of any Event of Default under the Lease which shall
include Amendment 001, and at any time while a default is continuing, Lessor
shall have the right to draw upon the Letter of Credit up to its full amount and
to apply the proceeds thereof first to any reasonable costs and expenses
incurred by Lessor in the enforcement of the terms of the Lease and the exercise
of  its rights and remedies, then to the unpaid balance of all sums payable
under the Lease, whether by acceleration or otherwise, with any excess proceeds
being refundable to Lessee, and Lessee remaining liable for any deficiency.

     5.  Waiver by Lessor of a default shall not constitute a continuing waiver
of default, of the same provision or any other provision of the Lease.
Additionally, failure of Lessor to draw upon the Letter of Credit at any time
shall not be construed as a waiver of Lessor's right to draw upon the Letter of
Credit as herein set forth at any other time.

     6.  The exercise by Lessor of its rights under this Agreement shall be
deemed to be in addition to and not in lieu of any other rights and remedies of
Lessor under the Lease, or any other document relating to the Lease and shall
not be construed in any manner to represent satisfaction of the obligations of
Lessee under or with respect to the Lease.
<PAGE>

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of
the date set forth above.

SEQUENOM, INC.                        COMDISCO LABORATORY AND SCIENTIFIC GROUP,
as Lessee                             A DIVISION OF COMDISCO, INC.
                                      as Lessor

By:________________________           By:_______________________________

Title:_____________________           Title:____________________________

Date:______________________           Date:_____________________________
<PAGE>

                                  DRAW REQUEST

                                                Letter of Credit No. ___________

[date]

Attention:  Letter of Credit Department

Gentlemen:

    The undersigned hereby draws on Irrevocable Standby Letter of Credit No. ,
dated  (the "Letter of Credit") issued by you in our favor.  Any capitalized
term used herein and not defined shall have its respective meaning as set forth
in the Letter of Credit.

    In connection with the drawing, the undersigned hereby certifies that:

    (1)  Pursuant to Equipment Schedule No. SG-, an Event of Default has
occurred thereunder and we are making this drawing under the Letter of Credit
pursuant to the Schedule.

    (2)  The amount of this request is $, which amount does not exceed the
current Letter of Credit amount.

    (3) The date here is not after the Expiration Date.

IN WITNESS WHEREOF, the undersigned has executed and delivered this request on
this  day of .

                               COMDISCO LABORATORY AND SCIENTIFIC GROUP,
                               A DIVISION OF COMDISCO, INC.

                               By:    SAMPLE
                                  --------------------------

                               Title:_________________________________
<PAGE>

                                  CERTIFICATE

  The Undersigned, a duly elected and acting ___________ Secretary of Sequenom,
Inc., a _____________ corporation (the "Company") does hereby certify as
follows:

    (A)   The following listed persons are duly elected and acting officers of
          the Company (the "Officers") in the capacity set forth opposite their
          respective names below and that the facsimile signatures are true and
          correct as of the date hereof; and

    (B)   The Officers are duly authorized, on behalf of the Company, to
          negotiate, execute and deliver the Global Master Rental Agreement
          dated as of May 4, 2000 and the Equipment Schedule(s) thereunder and
          all future Equipment Schedule(s) (the "Agreements") by and between the
          Company and Comdisco Laboratory and Scientific Group, a division of
          Comdisco, Inc.; and these Agreements are binding and authorized
          Agreements of the Company, enforceable in all respects in accordance
          with their terms.

NAME OF OFFICER          TITLE                    SIGNATURE

________________         _______________          ____________________

________________         _______________          ____________________

________________         _______________          ____________________

________________         _______________          ____________________

    WITNESS MY HAND and the corporate seal of the Company this _______ day of
___________________, 2000.

                                    ____________________________________

                                    ____________________________ Secretary
SEAL<PAGE>

                                                                   EXHIBIT 10.66

                                          *** Text Omitted and Filed Separately
                                          Confidential Treatment Requested Under
                                          17 C.F.R. Sections 200.80(b)(4),
                                          200.83 and 240.24b-2

                                 CONFIDENTIAL

                         STRATEGIC ALLIANCE AGREEMENT

This STRATEGIC ALLIANCE AGREEMENT (the "Agreement") effective as of May 3, 2000
(the "Effective Date") is made by and between Genaissance Pharmaceuticals, Inc.
(hereinafter referred to as "GENAISSANCE"), a Delaware corporation having its
principal place of business at Five Science Park, New Haven, Connecticut 06511
and Sequenom, Inc. (hereinafter referred to as "SEQUENOM") a Delaware
corporation having its principal place of business at 11555 Sorrento Valley
Road, San Diego, California 92121.

                                   RECITALS

WHEREAS, SEQUENOM has expertise in the development and utilization of mass
spectrometry for biopolymer analysis, and expertise in biopolymer assay design
(MassARRAY(TM) Assays), and more specifically, has developed SEQUENOM's
proprietary MassARRAY(TM)  technology for high-throughput DNA analysis
(hereinafter "MassARRAY") and whereas SEQUENOM is building a database of
variation in genes of commercial significance to the pharmaceutical industry;

WHEREAS, GENAISSANCE has expertise in discovering human genomic variation and in
correlating such variation with clinical endpoints, and more specifically is
building a database of such variation in genes of commercial significance to the
pharmaceutical industry (Isogenomics(TM) Database);

WHEREAS, GENAISSANCE desires to purchase certain MassARRAY Products (as
hereinafter defined) from SEQUENOM to be used for GENAISSANCE's Internal
Research Purposes (as hereinafter defined) and HAP(TM) Marker Genotyping
Collaborations (as hereinafter defined), and also desires that SEQUENOM design
MassARRAY Assays (as hereinafter defined) to be used in support of GENAISSANCE's
Internal Research Purposes and HAP(TM) Marker Genotyping Collaborations;

WHEREAS, SEQUENOM is willing to supply MassARRAY Products and to design
MassARRAY Assays for GENAISSANCE for its Internal Research Purposes and HAP(TM)
Marker Genotyping Collaborations in accordance with the terms and conditions set
forth in this Agreement;

WHEREAS, SEQUENOM AND GENAISSANCE wish to collaborate in developing MassARRAY
technology for use in clinical trials and clinical genetic tests and wish to
collaborate in marketing each others products and services;

NOW, THEREFORE, in consideration of the mutual covenants and promises contained
herein, GENAISSANCE and SEQUENOM (each a "party" or collectively the "parties")
agree as follows:
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
               CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                 CONFIDENTIAL

                            ARTICLE 1.  DEFINITIONS

1.1  "Affiliate" shall mean with respect to either party, a person or entity,
     including without limiting the generality of the foregoing, organizations,
     corporations, partnerships and joint ventures, that directly or indirectly
     through one or more intermediaries, controls, is controlled by or is under
     common control with such person or entity. "Control" (and, with correlative
     meanings, the term "controlled by" and "under common control with") means
     the possession of the power to direct or cause the direction of the
     management and policies of such person or entity, whether through the
     ownership of voting stock, by contract or otherwise. In the case of a
     corporation, "control" shall mean, among other things, the direct or
     indirect ownership of fifty percent (50%) or more of its outstanding voting
     stock.

1.1  "Commercial Genotyping Services" shall mean performing genotyping services
     in conjunction with a clinical diagnostic test to detect known disease
     mutations or known prognostic polymorphisms or performing genotyping
     services on a direct fee for service basis. For purposes of this Agreement,
     the parties agree that performance of genotyping by GENAISSANCE for
     Internal Research Purposes and for HAP(TM) Marker Genotyping Collaborations
     is excepted and not considered Commercial Genotyping Services under this
     definition.

1.3  DecoGen(TM) Software shall mean GENAISSANCE's software which is designed to
     curate, collate and mine in silico gene variation data and which contains
     algorithms for building haplotypes from SNPs and for identifying
     associations between genetic polymorphisms and phenotypes.

1.4  "Element" shall mean the SpectroCHIP(TM) technology, and the Reaction
     Components B, as set forth in Appendix B, required for the MassARRAY System
     to produce a mass spectrum from the reaction products located at a single
     defined area (a.k.a. "Position") located on the SpectroCHIP,***************
     ***************************************************************************
     ***************************************************************************
     By way of example, for the 96-D SpectroCHIP, each SpectroCHIP contains
     ninety six (96) Positions, so that for the MassARRAY System processing a
     SpectroCHIP that has a biopolymer sample ******************************,
     ninety six (96) Elements are used and consumed under this definition.

1.5  "Field of Use" shall mean Internal Research Purposes and HAP(TM) Marker
     Genotyping Collaborations. Commercial Genotyping Services are specifically
     excluded from the Field of Use.

1.6  "GENAISSANCE Know-How" shall mean any and all proprietary data,
     information, know-how, inventions, trade secrets, copyrights, regulatory
     submissions or other intellectual property of any kind, other than Patent
     Rights, owned or controlled by GENAISSANCE as of the Effective Date or
     during the term of this Agreement.

                                       2
<PAGE>

                                  CONFIDENTIAL

1.1   "Genolyzer(TM) Software" or "SpectroTYPER(TM) Software" shall mean
      SEQUENOM's software used in conjunction with the MassARRAY System to
      generate and store genotyping data, including sequences of primers used to
      detect SNPs, the nucleotides being detected, the mass spectrometry data
      relating to extension of such primers, and the genotypes generated from
      such data.

1.8   "HAP(TM) Marker Genotyping Collaborations" shall mean GENAISSANCE's in-
      house genotyping of SNPs pursuant to an agreement or collaboration with a
      third party, in which such genotyping is performed for the sole purposes
      of discovering, testing, confirming, or validating a SNP Association,
      including within the context of a clinical trial, and providing
      information to the third party regarding such association.

1.9   "HAP(TM) Marker Genotyping Collaborator" shall mean a third party,
      including but not limited to any pharmaceutical or biotechnology company,
      or any academic or nonprofit institution, for which GENAISSANCE performs
      genotyping for the purposes described in section 1.8.

1.10  "Internal Research Purposes" shall mean purposes and activities within
      GENAISSANCE that are limited to research and development. Internal
      Research Purposes includes SNP validation for GENAISSANCE's in-house
      disease specific projects. Internal Research Purposes does not mean and is
      not meant to include activities performed under grant money, funding, and
      non-funding arrangements with third party companies, enterprises, or
      institutions (for example, but not limited to pharmaceutical research or
      manufacturing organizations) under which results, products, or information
      from such activities are to be provided to the third party. Internal
      Research Purposes does not mean and does not include HAP(TM) Marker
      Genotyping Collaborations and does not mean and does not include
      Commercial Genotyping Services.

1.11  "MassARRAY Assay" or "Assay" shall mean an assay designed by SEQUENOM at
      the request of GENAISSANCE for the purpose of genotyping a particular
      Proprietary SNP or Non-proprietary SNP and to be used with the multi-step
      process described in Appendix C hereto, and such Assay shall include the
      nucleotide sequences of the amplification and extension primers, as well
      as allele-specific mass values, that are necessary for performing the
      Assay. For purposes of this Agreement, the parties agree that "MassARRAY
      Assays" shall mean all Assays which are designed by SEQUENOM at the
      request of GENAISSANCE after the Effective Date of this Agreement, as well
      as all Assays which were designed by SEQUENOM at the request of
      GENAISSANCE prior to the Effective Date of this Agreement for the SNPs
      listed in Appendix H hereto.

1.12  "MassARRAY Products" shall mean the MassARRAY System (as described and
      defined in Appendix A hereto, and as developed pursuant to sections 2.9.1
      and 2.9.2) and the MassARRAY Kit (as described and defined in Appendix B
      hereto).

1.13  "MassEXTEND(TM) Methods and Processes" shall mean the MassEXTEND(TM)
      Reaction as described and defined in Appendix C hereto and which is
      claimed under Patent Rights

                                       3
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
               CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                  CONFIDENTIAL

      including United States Patent Application Serial No. ********* and
      foreign equivalents thereof.

1.14  "Non-proprietary SNP" shall mean a SNP that is not claimed under Patent
      Rights of GENAISSANCE or a HAP(TM) Marker Genotyping Collaborator and that
      is not Confidential Information of GENAISSANCE or a HAP(TM) Marker
      Genotyping Collaborator.

1.15  "Patent Rights" shall mean ownership of or exclusive license rights to (i)
      any United States or foreign patent application, (ii) any issued United
      States patent or foreign patent and (iii) any continuation, continuation-
      in-part, divisional, reissue, re-examination, renewal, substitution,
      addition, extension, supplementary protection certificate or foreign
      counterpart thereof of any of the foregoing.

1.16  **************************************************************************
      **************************************************

1.17  "Proprietary SNP" shall mean a SNP that is claimed under Patent Rights of
      GENAISSANCE or a HAP(TM) Marker Genotyping Collaborator or that is
      Confidential Information of GENAISSANCE or a HAP(TM) Marker Genotyping
      Collaborator.

1.18  "SEQUENOM Know-How" shall mean any and all proprietary data, information,
      know-how, inventions, trade secrets, copyrights, regulatory submissions or
      other intellectual property of any kind, other than Patent Rights, owned
      or controlled by SEQUENOM as of the Effective Date or during the term of
      this Agreement.

1.19  "SNP" shall mean a single nucleotide polymorphism.

1.20  "SNP Association" shall mean an association between one or more SNPs and a
      phenotype, including but not limited to the presence of, or susceptibility
      for, any disease or condition in humans, or response to a drug, where such
      association is discovered using MassARRAY Assays in the Field of Use.

                ARTICLE 2.  PURCHASING, ORDERS AND COLLABORATION

2.1   GENAISSANCE agrees to purchase MassARRAY Products as identified in
      Appendices A and B, and SEQUENOM agrees to sell and deliver MassARRAY
      Products to GENAISSANCE. Such purchase, sale, and delivery shall be under
      the terms of this Agreement.

2.2   **************************************************************************
      **************************************************************************
      **************************************************************************
      **************************************************************************
      **************************************************************************
      **************************************************************************

                                       4
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
               CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                  CONFIDENTIAL

     ***************************************************************************
     **********.

2.3  GENAISSANCE agrees to use MassARRAY Products as its preferred genotyping
     technology as long as MassARRAY Products remain competitive with
     alternative genotyping technologies in terms of the following criteria:
     (i) cost per assay; (ii) high-throughput capacity; (iii) accuracy; and (iv)
     consistency with industry or regulatory standards.  GENAISSANCE shall
     notify SEQUENOM if it considers that MassARRAY Products are no longer
     competitive with an alternative genotyping technology.  In such a case,
     GENAISSANCE agrees to inform SEQUENOM of the specific reasons why
     GENAISSANCE believes the MassARRAY Products are not competitive and will,
     in good faith, provide SEQUENOM with an opportunity to address these
     reasons and an opportunity to better meet GENAISSANCE's needs.

2.4  This Agreement contains the exclusive terms and conditions which apply to
     all purchases of MassARRAY Products, notwithstanding any acknowledgment or
     other business forms ("forms" meaning and including GENAISSANCE purchase
     orders) transmitted by SEQUENOM or GENAISSANCE.  All orders for MassARRAY
     Products must reference this Agreement and all SEQUENOM and GENAISSANCE
     acknowledgments and transmittals will reference this Agreement and the
     applicable GENAISSANCE purchase order.

2.5  All orders for MassARRAY Products must specify delivery within ninety (90)
     days from the order date. All orders are subject to acceptance by SEQUENOM
     and to product availability. All orders accepted by SEQUENOM are firm and
     non-cancelable and SEQUENOM shall use its best efforts to fill such orders
     within ninety (90) days from the order date.

2.6  This Agreement does not constitute a purchase order.  Purchases hereunder
     shall be made utilizing GENAISSANCE's written purchase orders issued by
     GENAISSANCE.

2.7  GENAISSANCE will use its best efforts to supply SEQUENOM with a forecast of
     its intended purchases on at least a quarterly basis, and SEQUENOM shall
     advise GENAISSANCE within ten (10) business days of its ability to meet
     such forecast. If SEQUENOM advises that it can meet such forecast and
     SEQUENOM subsequently determines that it will be unable to meet such
     forecast, SEQUENOM shall inform GENAISSANCE within five (5) business days
     of its inability to meet such forecast and the parties will discuss
     alternative solutions for meeting the forecast. SEQUENOM shall use its best
     efforts to meet any forecast for which it advised GENAISSANCE that it would
     meet.

2.8  When requested by GENAISSANCE, SEQUENOM agrees to design MassARRAY Assays
     to be used by GENAISSANCE as set forth in Article 5 below. GENAISSANCE
     shall request a group of MassARRAY Assays at a time, with the number of
     assays in such group to be mutually agreed upon, and shall provide SEQUENOM
     with the identity of, known alleles of, and local sequence information
     surrounding the SNPs to be

                                       5
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
               CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                  CONFIDENTIAL

     genotyped with the MassARRAY Assays.  SEQUENOM agrees to advise
     GENAISSANCE, within five (5) business days of receipt of such request, the
     expected delivery date for the group of MassARRAY Assays and shall use its
     best efforts to meet this date.  Physical samples of primers in aliquot
     form and/or validation of a MassARRAY Assay will only be provided by
     SEQUENOM at GENAISSANCE's expense and subject to the agreement of and at a
     price to be determined by the parties. GENAISSANCE will be responsible for
     and bear all of the costs associated with purchasing and performing quality
     control experiments on all MassARRAY Assays that it uses or plans to use.

     2.8.1  SEQUENOM, at its option, shall have the right to terminate its
            obligation to design MassARRAY Assays at any time starting six (6)
            months after the Effective Date of this Agreement provided that
            SEQUENOM shall provide GENAISSANCE with three (3) months advance
            notice of such termination.

2.9  SEQUENOM is interested in providing its customers with MassARRAY Products
     together with Standard Operating Procedures (hereinafter "SOPs") and
     validation materials that would assist its customers in establishing that a
     laboratory using such MassARRAY Products for performing high-throughput
     genotyping of SNPs in pharmacogenetic-based clinical trials is compliant
     with US regulatory standards as set forth in the Clinical Laboratory
     Improvement Amendments of 1988 ("CLIA"), and possibly other governmental
     regulatory standards.  GENAISSANCE is also interested in using MassARRAY
     Products in conjunction with its DecoGen(TM) Software in a high-throughput
     genotyping facility that is compliant with all U.S. regulatory standards
     and has expertise in obtaining certification of such compliance.  As a
     result, the parties agree as follows:

     2.9.1  The parties agree to collaborate to define and develop a standard
            configuration of a Moderate-Throughput MassARRAY System for use only
            within the Field of Use, including but not limited to, clinical
            molecular diagnostic laboratory uses within the Field of Use. This
            Moderate-Throughput MassARRAY System will be designed to process
            approximately ******************** assays per day. This Moderate-
            Throughput System will be purchased and used by GENAISSANCE only in
            the Field of Use after completion of satisfactory design,
            implementation and testing by the parties, and contingent upon the
            parties' mutual agreement on price and delivery schedule pursuant to
            section 4.2.

     2.9.2  The parties further agree to define and develop a standard
            configuration of a High-Throughput MassARRAY Facility for use only
            within the Field of Use, including but not limited to, clinical
            molecular diagnostic laboratory uses within the Field of Use. This
            High-Throughput MassARRAY Facility will be designed to process up to
            ************************** assays per day. The components of this
            High-Throughput Facility will be purchased and used by GENAISSANCE
            only in the Field of Use after completion of satisfactory design,
            implementation and testing by the parties and contingent upon the
            parties' mutual agreement on price and delivery schedule pursuant to
            section 4.2.

                                       6
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
               CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                  CONFIDENTIAL

     2.9.3  GENAISSANCE agrees to collaborate with SEQUENOM to define and
            develop a standard set of molecular genetic reagents (hereinafter
            "Reagents") and SOPs for use with the Reagents and each of the
            standard MassARRAY configurations developed pursuant to this section
            2.9. The Reagents and SOPs will be designed to functionally validate
            the standard MassARRAY configurations as part of the process of
            certifying that a laboratory performing genotyping assays using one
            of the standard MassARRAY configurations defined herein is compliant
            with CLIA regulations for operation of clinical molecular genetics
            laboratories.

            (a)  The Reagents will include MassARRAY Assays for genotyping a set
                 of *** well characterized Non-proprietary SNPs in a set of
                 ***************** DNA specimens. All of the DNA specimens will
                 be derived from unrelated *************** samples that are
                 available to research and diagnostic laboratories through the
                 American Type Culture Collection (ATCC). SEQUENOM will design
                 and retain ownership of the Assays provided that GENAISSANCE
                 shall receive a ************, non-exclusive license, without
                 the right to transfer or sublicense, to use such Assays in the
                 Field of Use. GENAISSANCE will not provide any of these
                 Reagents to SEQUENOM or third party laboratories. SEQUENOM may,
                 at its discretion, choose to package any or all of these
                 materials as a kit for sale and distribution to its customers.

            (b)  The SOPs will include detailed instructions for performing the
                 Assays using the Reagents with either the Moderate-Throughput
                 MassARRAY System or the High-Throughput MassARRAY Facility in a
                 manner consistent with CLIA regulations for operation of
                 clinical molecular genetics laboratories. GENAISSANCE shall
                 design and retain ownership of these SOPs, provided that
                 SEQUENOM shall receive a ************, non-exclusive license to
                 use and sell the SOPs, and shall have the right to sublicense
                 the SOPs to customers of SEQUENOM for use in conjunction with
                 one of the standard MassARRAY configurations designed pursuant
                 to this Agreement. GENAISSANCE shall, at its sole discretion,
                 have the right to modify the Reagents and SOPs for its internal
                 use and such modifications will remain the Confidential
                 Information of GENAISSANCE.

            (c)  The parties agree that neither party shall guarantee or warrant
                 performance of the Reagents and/or SOPs for use in obtaining
                 certification that a laboratory is in compliance with CLIA
                 regulations for operation of clinical molecular genetics
                 laboratories or for any other purpose.

     2.9.4  SEQUENOM agrees to provide GENAISSANCE with clear, understandable
            documentation regarding ************************************
            *********** to the extent necessary to allow GENAISSANCE to define
            and produce data retrieval tools (hereinafter "Data Tools") for use
            with GENAISSANCE's DecoGen(TM) Software, electronic notebooks and
            any

                                       7
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
               CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                 CONFIDENTIAL

             laboratory information management system selected by GENAISSANCE.
             GENAISSANCE agrees that such documentation shall only be used to
             develop the Data Tools. GENAISSANCE shall retain complete title and
             ownership to such Data Tools with the right to license or transfer
             such Data Tools only to those HAP(TM) Marker Genotyping
             Collaborators that have a license from GENAISSANCE to use
             DecoGen(TM) Software and, under a separate license agreement with
             SEQUENOM, have a license to Genolyzer(TM) Software.

     2.9.5   During the term of this Agreement, the parties agree to negotiate
             in good faith to extend the collaborations described in this
             section 2.9 to other configurations of MassARRAY technology and
             other SEQUENOM products that are currently under development or
             that may be developed in the future by SEQUENOM as well as to
             future versions of the DecoGen(TM) Software or other software
             developed by GENAISSANCE.

     2.9.6   In the unlikely event that the parties can not agree on the
             definition of a standard MassARRAY configuration pursuant to
             section 2.9.1 or section 2.9.2, or specifications therefor, then
             SEQUENOM will use its best efforts to support alternative
             MassARRAY-based configurations and specifications installed at
             GENAISSANCE.

     2.10   The parties each agree to recommend the other party's products and
            services to potential customers in the pharmaceutical,
            biotechnology, and agricultural markets, and refer publicly to one
            another as Strategic Partners. SEQUENOM will refer to GENAISSANCE as
            a provider of technology that connects genomic variation with
            clinical outcomes and GENAISSANCE will refer to SEQUENOM as its
            provider of high-throughput genotyping technology for use in genomic
            variation and clinical association studies. Each party will make
            available to the other party marketing and technical material,
            including non-proprietary data, to be incorporated into public
            lectures where appropriate. Each party will also make available a
            representative to present its respective technology in private
            meetings with third party potential customers, where it is
            determined that this will support the execution of a sale.

     2.11   Within six months of executing this Agreement, the parties will
            mutually agree upon a collaborative marketing scheme, which shall
            include at least: (a) details of joint marketing tools (e.g. joint
            events, web site cross-linking); (b) a procedure to establish which
            party shall serve as `primary lead' when both parties independently
            enter into discussions with the same potential customer; and (c)
            financial incentives (e.g. royalties or `finder's fees'), if any, to
            be provided when one party secures new business for the other party.

     2.12   Throughout the term of this Agreement, each party will designate a
            dedicated staff member as its Strategic Alliance Manager whose
            primary responsibility will be the successful implementation of this
            Agreement. SEQUENOM designates *************, Ph.D. as its initial
            Strategic Alliance Manager and GENAISSANCE designates Mark

                                       8
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
               CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                 CONFIDENTIAL

           Rabin, Ph.D. as its initial Strategic Alliance Manager. Each party
           agrees to notify the other party within ten (10) business days of a
           change in its Strategic Alliance Manager.

                ARTICLE 3. DELIVERY, SHIPMENT AND RISK OF LOSS

     3.1   Delivery of MassARRAY Products is subject to acceptance of the order
           by SEQUENOM and to product availability, and to SEQUENOM's lead times
           which may change from time to time.

     3.2   SEQUENOM will ship according to SEQUENOM's standard commercial
           practice as described in Appendix D. Special packing or shipping
           instructions requested by GENAISSANCE must be agreed to by SEQUENOM
           in writing, and any charges will be billed to GENAISSANCE.

     3.3   All shipments by SEQUENOM shall be FOB SEQUENOM's point of
           manufacture in the United States, provided that if SEQUENOM has a
           point of manufacture in Europe, then any shipments by SEQUENOM to
           GENAISSANCE's facilities in Europe shall be FOB SEQUENOM's point of
           manufacture in Europe. Title to and risk of loss for the MassARRAY
           Products shall pass to GENAISSANCE upon delivery by SEQUENOM to a
           carrier designated by GENAISSANCE or selected by SEQUENOM if
           GENAISSANCE does not designate a carrier.

                      ARTICLE 4. PRICE AND PAYMENT TERMS

     4.1   MassARRAY System Price. SEQUENOM has delivered one MassARRAY System
           ----------------------
           to GENAISSANCE which consisted of the items listed on GENAISSANCE's
           Purchase Order No. *****, which is attached as Appendix G hereto, and
           for which GENAISSANCE has agreed to**********************************
           *******************************

     4.2   GENAISSANCE agrees to purchase at ************* additional
           SpectroSCAN(TM) array mass spectrometers, as well as the accompanying
           components comprising one or both of the MassARRAY standard
           configurations developed pursuant to sections 2.9.1 and 2.9.2, the
           configuration, price, and delivery schedule of which to be mutually
           agreed upon by the parties, with the understanding that the price and
           delivery schedule shall reflect the ************************* of
           GENAISSANCE.

     4.3   SEQUENOM agrees to upgrade, ************ to GENAISSANCE, the
           MassARRAY Systems purchased by GENAISSANCE pursuant to sections 4.1
           and 4.2 to provide a capacity for simultaneously processing three
           hundred eighty-four (384) samples through all steps in the Assay
           described in Appendix C. SEQUENOM agrees to perform such upgrade
           within ten (10) business days that such upgrade becomes commercially
           available and agrees that such upgrade shall include replacement of
           components of the MassARRAY Systems installed at GENAISSANCE if
           necessary to achieve such capacity.

                                       9
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
               CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                 CONFIDENTIAL

     4.4   MassARRAY Kit Price. Except as otherwise provided in this section 4.4
           -------------------
           and section 4.5, the price of a MassARRAY Kit
           **************************************** *******. This price for the
           MassARRAY Kit is based upon a fee ***************** *********** per
           Element. This price is for the MassARRAY Kit set forth in Appendix B,
           each Kit including a ten (10) chip 384-D SpectroCHIP(TM) pack,
           wherein each SpectroCHIP(TM) chip contains three-hundred eighty four
           (384) Positions. Until the 384-D SpectroCHIP becomes available,
           SEQUENOM will sell GENAISSANCE MassARRAY Kits that include a ten (10)
           chip 96-D SpectroCHIP(TM) pack, wherein each SpectroCHIP(TM) chip
           contains ninety six (96) Positions, for a price *****************
           ****************************. This price for MassARRAY Kits having
           the ten (10) chip 96-D SpectroCHIP(TM) pack is based upon the same
           fee ********************** ****** per Element. The parties agree that
           the price per Element set forth in this section 4.4 shall be reviewed
           every six months and shall be reduced if necessary to assure that
           GENAISSANCE receives ************************* as set forth in
           section 2.2. Should the parties agree to extend this Agreement beyond
           its three (3) year duration, SEQUENOM reserves the right to adjust
           the price for its MassARRAY Kits at its option, provided that the
           adjusted price shall reflect GENAISSANCE's **************** ***** as
           set forth in section 2.2. Payments for the MassARRAY Kits will be due
           thirty (30) days from the date of shipment. Upon shipment of
           MassARRAY Kits, SEQUENOM will submit an invoice reflecting an invoice
           number, date, remit to address, purchase order number, quantity
           ordered, unit price, and any applicable tax and shipping and handling
           charges. The configuration of the MassARRAY Kit may change and/or be
           improved from time to time and may or may not be accompanied by a
           change in purchase price, although the fees per Element agreed to
           will not increase during the three (3) year duration of this
           Agreement.

     4.5   Discounted MassARRAY Kit Pricing Based Upon Increased Consumption.
           -----------------------------------------------------------------
           SEQUENOM agrees to charge GENAISSANCE a reduced Element fee other
           than that set forth under section 4.4 above, in the event and upon
           the condition that GENAISSANCE, during a twelve month calendar year,
           achieves Element consumption milestones as set forth below, according
           to a scale where the Element fee is reduced as consumption increases.
           For example, as shown in the table below, should GENAISSANCE consume
           between ****************************************** ******************
           Elements in a given calendar year, GENAISSANCE will be charged an
           Element fee of ******************************* per Element rather
           than ************************** per Element as set forth under
           section 4.4. In such a case, GENAISSANCE will receive****************
           ***********************, upon reaching such milestones, and *********
           ******************************************.

--------------------------------------------------------------------------------
ELEMENTS CONSUMED                                          ***************
                       ************       ************
PER CALENDAR YEAR                                              *******
--------------------------------------------------------------------------------
ELEMENT FEE               ****                ****              ****
--------------------------------------------------------------------------------

                                       10
<PAGE>

     ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
     CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                 CONFIDENTIAL

4.6  Manner of Payment.  Payments to be made by GENAISSANCE to SEQUENOM under
     -----------------
     this Agreement shall be payable in United States dollars.

          ARTICLE 5.  INTELLECTUAL PROPERTY AND LIMITED RIGHT TO USE

5.1  By this Agreement, and subject to the terms and conditions set forth under
     section 5.1.1 of this Article 5, with the purchase of MassARRAY Kits,
     SEQUENOM grants GENAISSANCE a world-wide, non-exclusive, limited right, to
     use, without the right to permit third parties to use, the MassARRAY Kits,
     in conjunction with the MassARRAY System, for the defined Field of Use.

     5.1.1  The MassARRAY Kits provided under this Agreement may be used in
            performing SEQUENOM's proprietary MassEXTEND(TM) Methods and
            Processes claimed under Patent Rights including United States Patent
            Application Serial No. ********* and foreign equivalent Patent
            Rights. The pricing of the MassARRAY Kit set forth in sections 4.4
            and 4.5 includes a prepaid royalty in consideration for which
            SEQUENOM grants GENAISSANCE a non-exclusive right without transfer
            or sublicense rights, under United States Patent Application Serial
            No. *********, foreign equivalent Patent Rights and SEQUENOM Know-
            How to use the MassARRAY Kits to perform SEQUENOM's proprietary
            MassEXTEND(TM) Methods and Processes, such right granted being
            limited to the number of Elements provided per MassARRAY Kit
            purchased, and such right granted being limited to use by
            GENAISSANCE for the defined Field of Use.

5.2  The purchase price and royalty terms agreed to under Article 4 and this
     Article 5 of this Agreement, are based upon the parties' mutual
     understanding of the limited rights and the limited Field of Use placed on
     GENAISSANCE's use of MassARRAY Products provided for under this Article.
     Any other uses of the MassARRAY Products, and any terms and conditions
     related thereto, must be agreed to, in writing, by the parties. With the
     exception of the rights granted under this Article 5, no other right or
     license is granted to GENAISSANCE either directly, indirectly, by
     implication, estoppel, or otherwise by SEQUENOM under this limited grant.

5.3  All MassARRAY Assays for Proprietary SNPs are hereby designated GENAISSANCE
     Confidential Information and SEQUENOM's use of such assays shall be limited
     as set forth in this section 5.3 and Article 11.

     5.3.1  For the avoidance of doubt, SEQUENOM may make, use, offer to sell
            and sell MassARRAY Assays for genotyping Proprietary SNPs provided
            that SEQUENOM validates such Assays independently of any GENAISSANCE
            Confidential Information as defined in section 11.1, provided that
            such Proprietary SNPs have lost their status as Confidential
            Information or never were Confidential Information and that such
            Assays do not infringe any issued claim under Patent Rights of
            GENAISSANCE or a HAP(TM) Marker Genotyping Collaborator.

                                       11
<PAGE>

     ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
     CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                 CONFIDENTIAL

     5.3.2  Except as explicitly provided by section 5.3.1, the parties agree
            that section 5.3.1 does not grant to SEQUENOM any license to make,
            use, offer to sell or sell the MassARRAY Assays referenced in
            section 5.3.1 under any Patent Rights claiming such Assays and does
            not grant to SEQUENOM an exemption for liability for any damages
            provided under any patent protection associated with such Patent
            Rights.

     5.3.3  The parties agree that nothing in this Agreement, including any and
            all of the language in this Article 5, is intended to grant
            GENAISSANCE a license to perform SEQUENOM's proprietary
            MassEXTEND(TM) Methods and Processes, or to grant to GENAISSANCE a
            license to any Patent Rights of SEQUENOM, based solely upon the
            designation of MassARRAY Assays for Proprietary SNPs as "GENAISSANCE
            Confidential Information" (as set forth under section 5.3) or
            otherwise by implication under this Agreement. For the avoidance of
            doubt, and by way of example only, should this Agreement terminate
            or expire, while GENAISSANCE possesses and own the rights to the
            MassARRAY Assays (as defined in section 1.11) for Proprietary SNPs,
            GENAISSANCE does not possess, control, or own any interest in any
            Patent Rights of SEQUENOM, including any and all Patent Rights to
            SEQUENOM's proprietary MassEXTEND(TM) Methods and Processes. If
            MassARRAY Assays for Proprietary SNPs have utility outside the scope
            of SEQUENOM's Patent Rights, then GENAISSANCE is free to exploit
            such utility, however, MassARRAY Assays for Proprietary SNPs may not
            be used within the scope of any of SEQUENOM's Patent Rights unless,
            and only upon the condition that MassARRAY Assays for Proprietary
            SNPs are used with MassARRAY Products purchased from SEQUENOM and
            the written license agreement provisions of sections 5.1 and 5.1.1
            are in effect between the parties and are complied with by
            GENAISSANCE.

5.4  All MassARRAY Assays for Non-proprietary SNPs are hereby designated
     SEQUENOM Confidential Information and GENAISSANCE's use of such Assays
     shall be limited as set forth in this section 5.4 and Article 11.

     5.4.1  By this Agreement, SEQUENOM grants to GENAISSANCE a world-wide,
            **********, non-exclusive license right, without the right to
            sublicense or transfer, to make and use MassARRAY Assays for Non-
            proprietary SNPs, only in the defined Field of Use and only with
            MassARRAY Products purchased from SEQUENOM.

     5.4.2  For the avoidance of doubt, the parties agree that GENAISSANCE is
            free to make, use, offer to sell and sell assays for genotyping Non-
            proprietary SNPs when GENAISSANCE designs and validates such assays
            independently of any SEQUENOM Confidential Information as defined in
            sections 5.4 and 11.1, provided that such assays do not infringe any
            issued claim under Patent Rights of SEQUENOM.

                                       12
<PAGE>

     ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
     CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                 CONFIDENTIAL

     5.4.3  Except as explicitly provided by section 5.4.2, the parties agree
            that section 5.4.2 does not grant to GENAISSANCE any license to
            make, use, offer to sell or sell the assays referenced in section
            5.4.2 under any Patent Rights claiming such assays and does not
            grant to GENAISSANCE an exemption for liability for any damages
            provided under any patent protection associated with such Patent
            Rights.

5.5  GENAISSANCE shall have sole ownership of all right, title and interest in
     all SNP Associations that are discovered by GENAISSANCE, or codiscovered by
     GENAISSANCE and a HAP(TM) Marker Genotyping Collaborator, using a MassARRAY
     Assay.

5.6  SEQUENOM represents and agrees that all employees or others acting on its
     behalf pursuant to this Agreement shall be obligated under a binding
     written agreement to assign to SEQUENOM all inventions made or conceived by
     such employee or other person.

5.7  GENAISSANCE represents and agrees that all employees or others acting on
     its behalf pursuant to this Agreement shall be obligated under a binding
     written agreement to assign to GENAISSANCE all inventions made or conceived
     by such employee or other person.

5.8  Except as provided under section 5.3.1, SEQUENOM agrees that it shall
     require a license or prior written permission from GENAISSANCE to use,
     market or sell MassARRAY Assays for Proprietary SNPs.

5.9  Except as otherwise expressly provided in this Agreement, under no
     circumstances shall a party hereto, as a result of this Agreement, obtain
     any ownership interest in or other right to any technology, know-how,
     patents, patent applications, data, products, or biological materials of
     the other party, including items owned, controlled or developed by the
     other party, or transferred by the other party to said party, at any time
     pursuant to this Agreement. Any compounds, technology or know-how derived,
     developed or acquired by either party independent of this Agreement or
     Confidential Information derived from this Agreement shall be the property
     of such party.

5.10 SEQUENOM recognizes that GENAISSANCE would like HAP(TM) Marker Genotyping
     Collaborators to have access to the MassARRAY Products that GENAISSANCE is
     provided with under this Agreement. SEQUENOM agrees that it will grant
     licenses to MassARRAY Products to HAP(TM) Marker Genotyping Collaborators
     on commercially reasonable terms. In addition, SEQUENOM agrees that it will
     grant to HAP(TM) Marker Genotyping Collaborators a ********** non-exclusive
     license to make and use MassARRAY Assays designed for GENAISSANCE by
     SEQUENOM for Non-proprietary SNPs, provided that such licenses shall be
     limited to the Field of Use defined herein and shall only be granted to
     those HAP(TM) Marker Genotyping Collaborators who have a license under a
     separate agreement with SEQUENOM to use MassARRAY Products. While the
     license grants referred to in this section 5.11 will not be unreasonably
     withheld by SEQUENOM, SEQUENOM does reserve the right to abstain from
     granting a license to any HAP(TM) Marker Genotyping Collaborator that is a

                                       13
<PAGE>

                                 CONFIDENTIAL

     competitor of SEQUENOM or that is otherwise not appropriate for a license
     grant in the sound and reasonable business judgment of SEQUENOM.

5.11 The parties agree that a HAP(TM) Marker Genotyping Collaborator is a third-
     party beneficiary of the provisions of section 5.11 and shall have the
     right to enforce such provisions against SEQUENOM.

                      ARTICLE 6.  INSPECTION/AUDIT RIGHTS

6.1  Upon the written request of SEQUENOM, GENAISSANCE shall permit an
     independent certified public accountant selected by SEQUENOM and acceptable
     to GENAISSANCE, which acceptance shall not be unreasonably withheld, to
     have access during normal business hours to such records of GENAISSANCE as
     may be reasonably necessary to verify GENAISSANCE's compliance with the
     terms of this Agreement, in respect of any fiscal year ending not more than
     twenty-four (24) months prior to the date of such request. SEQUENOM and
     GENAISSANCE shall use commercially reasonable efforts to schedule all such
     verifications within forty-five (45) days after SEQUENOM makes its written
     request. All such verifications shall be conducted not more than once in
     each calendar year. SEQUENOM agrees that all information subject to review
     under this section 6.1 or under any agreement with a HAP(TM) Marker
     Genotyping Collaborator is confidential and that SEQUENOM shall cause its
     independent certified public accountant to retain all such information in
     confidence and to execute a written agreement indicating the same.
     SEQUENOM's independent certified public accountant shall only report to
     SEQUENOM that information directly relating to compliance with the terms of
     this Agreement and shall not disclose to SEQUENOM any other information of
     GENAISSANCE or its HAP(TM) Marker Genotyping Collaborators.

6.2  Upon the written request of GENAISSANCE, SEQUENOM shall permit an
     independent certified public accountant selected by GENAISSANCE and
     acceptable to SEQUENOM, which acceptance shall not be unreasonably
     withheld, to have access during normal business hours to such records of
     SEQUENOM as may be reasonably necessary to verify SEQUENOM's compliance
     with the terms of this Agreement, in respect of any fiscal year ending not
     more than twenty-four (24) months prior to the date of such request.
     SEQUENOM and GENAISSANCE shall use commercially reasonable efforts to
     schedule all such verifications within forty-five (45) days after
     GENAISSANCE makes its written request. All such verifications shall be
     conducted not more than once in each calendar year. GENAISSANCE agrees that
     all information subject to review under this section 6.2 is confidential
     and that GENAISSANCE shall cause its independent certified public
     accountant to retain all such information in confidence and to execute a
     written agreement indicating the same. GENAISSANCE's independent certified
     public accountant shall only report to GENAISSANCE that information
     directly relating to compliance with the terms of this Agreement and shall
     not disclose to GENAISSANCE any other information of SEQUENOM.

                                       14
<PAGE>

                                 CONFIDENTIAL

                       ARTICLE 7.  TERM AND TERMINATION

7.1. The term of this Agreement will be from the Effective Date and will
     continue for a period of three (3) years, unless terminated by a party or
     the parties under one of the provisions of this Article 7.

7.2. This Agreement shall terminate upon written notice by one party to the
     other party in the event the other party shall become insolvent, asks its
     creditors for a moratorium, files a bankruptcy petition, or suffers
     appointment of a temporary or permanent receiver, trustee, or custodian,
     for all or a substantial portion of its assets.

7.3. Either party may terminate this Agreement for default by the other party in
     performing any of its material obligations under this Agreement by
     notifying the other party in writing of such default and allowing the other
     party thirty (30) days within which to cure such default, unless the
     default is the failure to pay money, in which case the defaulting party
     shall have only ten (10) business days to cure such default after receiving
     written notice of non-payment. If such default is not cured within thirty
     (30) days from receipt of such notice of default (or ten (10) business days
     in the case of non-payment of money owed), the non-defaulting party may
     terminate this Agreement by written notice to the defaulting party.

7.4. GENAISSANCE may terminate this Agreement if, in its sole judgement,
     SEQUENOM has failed to make MassARRAY Products competitive pursuant to
     section 2.3, by providing SEQUENOM thirty (30) days written notice of such
     termination.

7.5. In addition to the other grounds set forth in this Article 7, GENAISSANCE
     may terminate this Agreement by providing SEQUENOM thirty (30) days written
     notice if GENAISSANCE reasonably believes that this Agreement is no longer
     consistent with GENAISSANCE's overall business strategy.

7.6. Effect of Expiration or Termination of Agreement.  Within thirty (30) days
     -------------------------------------------------
     after expiration or termination under this Article 7, each party shall
     return to the other party or destroy any and all Confidential Information
     provided by the other party pursuant to this Agreement according to section
     11.3. GENAISSANCE shall have the right to use all MassARRAY Kits for which
     GENAISSANCE has paid and are in GENAISSANCE's possession at the time of
     termination, and the licenses granted GENAISSANCE pursuant to sections 5.1
     and 5.1.1 shall continue until all such MassARRAY Kits are used. Except to
     the extent expressly provided to the contrary, the rights and obligations
     of the parties pursuant to Articles 6, 7, 11, and 12 and sections 5.3,
     5.3.1, 5.3.2, 5.3.3, 5.4, 5.4.1, 5.4.2, 5.4.3, 5.5, 5.6, 5.7, 5.8, 5.9,
     14.3, 14.5, 14.6 and 14.15 shall survive the expiration or termination of
     this Agreement. Any and all rights of SEQUENOM to payments accrued through
     expiration or termination as well as obligations of the parties under firm
     orders for purchase and delivery of MassARRAY Products at the time of such
     expiration or termination shall remain in effect, except that SEQUENOM will
     have no obligation to sell and deliver MassARRAY Products that have
     delivery dates more than three (3) months after the date of termination,
     and in the case of termination under sections 7.2 or

                                       15
<PAGE>

     ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
     CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                 CONFIDENTIAL

     7.3, the terminating party has discretion in electing whether obligations
     under firm orders will remain in effect.

                    ARTICLE 8.  INSTALLATION AND ACCEPTANCE

8.1  Installation of each MassARRAY System by SEQUENOM at a location designated
     by GENAISSANCE is included in the price under sections 4.1 and 4.2.
     SEQUENOM shall install each MassARRAY System in accordance with SEQUENOM's
     standard installation practice as defined in Appendices D and E hereto, or
     as amended in the future by mutual written agreement of the parties, and
     SEQUENOM will use commercially reasonable efforts to schedule and complete
     installation in a timely fashion.  GENAISSANCE and SEQUENOM will cooperate
     with each other to coordinate the installation effort.

8.2  Installation shall be complete, and acceptance by GENAISSANCE shall occur,
     when the MassARRAY System passes SEQUENOM's standard installation and test
     procedures as defined in Appendices D and E hereto, or as amended in the
     future by mutual written agreement of the parties.  In the event the
     MassARRAY System delivered will not pass SEQUENOM's standard installation
     and test procedures, SEQUENOM will use reasonable commercial efforts to
     make the necessary adjustments and/or to replace the MassARRAY System in
     whole or in part until the MassARRAY System performs as intended and passes
     such tests.

                             ARTICLE 9.  TRAINING

9.1  Included in the price under sections 4.1 and 4.2, SEQUENOM will train
     designated GENAISSANCE employees in the installation, use, and routine
     maintenance of the MassARRAY Products in accord with SEQUENOM's standard
     training program as described in Appendices E and F hereto, or as amended
     in the future by mutual written agreement of the parties, and at a mutually
     convenient time for the parties.  GENAISSANCE may request from time to
     time, due to additional instrument purchases, employee changes, increased
     use, or otherwise, additional training as the need arises.  SEQUENOM will
     provide additional training according to a mutually convenient schedule and
     at a price to be mutually agreed that will reflect GENAISSANCE's
     *********************.

                   ARTICLE 10.  REPRESENTATIONS AND WARRANTY

10.1 Representations, Warranties and Covenants of GENAISSANCE.  GENAISSANCE
     ---------------------------------------------------------
     represents and warrants to and covenants with SEQUENOM that:

          (a)  GENAISSANCE is a corporation duly organized, validly existing and
               in corporate good standing under the laws of Delaware;

          (b)  GENAISSANCE has the legal right, authority and power to enter
               into this Agreement;

                                       16
<PAGE>

                                 CONFIDENTIAL

          (c)  GENAISSANCE has taken all necessary action to authorize the
               execution, delivery and performance of this Agreement;

          (d)  upon the execution and delivery of this Agreement, this Agreement
               shall constitute a valid and binding obligation of GENAISSANCE
               enforceable in accordance with its terms, except as
               enforceability may be limited by applicable bankruptcy,
               insolvency, reorganization, moratorium or similar laws affecting
               creditors' and contracting parties' rights generally and except
               as enforceability may be subject to general principles of equity
               (regardless of whether such enforceability is considered in a
               proceeding in equity or at law);

          (e)  the performance of its obligations under this Agreement will not
               conflict with its charter documents or result in a breach of any
               agreements, contracts or other arrangements to which it is a
               party; and

          (f)  GENAISSANCE will not during the term of this Agreement enter into
               any agreements, contracts or other arrangements that would be
               inconsistent with its obligations under this Agreement.

10.2 Representations, Warranties and Covenants of SEQUENOM. SEQUENOM represents
     ------------------------------------------------------
     and warrants to and covenants with GENAISSANCE that:

          (a)  SEQUENOM is a corporation duly organized, validly existing and in
               corporate good standing under the laws of Delaware;

          (b)  SEQUENOM has the legal right, authority and power to enter into
               this Agreement;

          (c)  SEQUENOM has taken all necessary action to authorize the
               execution, delivery and performance of this Agreement;

          (d)  upon the execution and delivery of this Agreement, this Agreement
               shall constitute a valid and binding obligation of SEQUENOM
               enforceable in accordance with its terms, except as
               enforceability may be limited by applicable bankruptcy,
               insolvency, reorganization, moratorium or similar laws affecting
               creditors' and contracting parties' rights generally and except
               as enforceability may be subject to general principles of equity
               (regardless of whether such enforceability is considered in a
               proceeding in equity or at law);

          (e)  the performance of its obligations under this Agreement will not
               conflict with its charter documents or result in a breach of any
               agreements, contracts or other arrangements to which it is a
               party;

          (f)  to the best of SEQUENOM'S knowledge, GENAISSANCE's use of
               MassARRAY Products and practice of MassEXTEND(TM) Methods and
               Processes in accordance with the product information, notices,
               and instructions for use provided therewith, do not and will not
               infringe any issued patent or valid copyright of any third party
               that is issued or registered prior to the effective date of this
               Agreement, respectively; and

                                       17
<PAGE>

                                 CONFIDENTIAL

            (g)  SEQUENOM will not during the term of this Agreement enter into
                 any agreements, contracts or other arrangements that would be
                 inconsistent with its obligations under this Agreement.

10.3 Limited Warranty Relating to MassARRAY Products.  SEQUENOM warrants that
     ------------------------------------------------
     the MassARRAY System will be free from defects in materials and workmanship
     and will conform to SEQUENOM's current specifications, or as amended in the
     future by mutual written agreement of the parties, and perform accordingly,
     from the time of installation and for a period of at least one (1) year
     thereafter, so long as the MassARRAY System remains unchanged and in the
     original condition supplied by SEQUENOM. SEQUENOM warrants that the
     MassARRAY Kits will be free from defects in materials and workmanship and
     will conform to SEQUENOM's specifications as defined in Appendix C hereto,
     or as amended in the future by mutual written agreement of the parties, and
     perform accordingly, for a period of at least two (2) months from the date
     of shipment, so long as the MassARRAY Kits are stored according to
     specifications as defined in Appendix C hereto, or as amended in the future
     by mutual written agreement of the parties, and remain unchanged and in the
     original condition supplied by SEQUENOM. The foregoing warranty does not
     include periodic maintenance or calibration recommended for some MassARRAY
     Products. This warranty does not apply to defects resulting from improper
     or inadequate maintenance or calibration by GENAISSANCE; defects resulting
     from hardware, software, interfacing, or supplies provided by parties other
     than SEQUENOM; defects resulting from unauthorized modification,
     maintenance, or repair, or improper use or operation outside of SEQUENOM's
     specifications for the MassARRAY Products or by personnel not authorized by
     SEQUENOM, and; defects resulting from abuse, negligence, accident, loss or
     damage in transit. In addition, this warranty does not apply to damage due
     to (1) environmental conditions at the site of installation; (2) operator
     failure to perform standard operating procedures and routine maintenance as
     prescribed in the operator manuals; (3) moving (by other than SEQUENOM
     authorized personnel) the MassARRAY System from its installed location; (4)
     exposure of the MassARRAY Products to Bio-Safety Level 3 or 4 (as defined
     by the United States Occupational Health and Safety Administration) agents;
     or (5) exposure to radioactivity.

     10.3.1  SEQUENOM's sole obligation and liability for any breach of the
             limited warranty set forth in section 10.3 shall be at SEQUENOM's
             sole discretion and option: (1) to replace the MassARRAY Products,
             in whole or in part, provided that GENAISSANCE notifies SEQUENOM of
             the defects, SEQUENOM directs GENAISSANCE to return the defective
             MassARRAY Products to SEQUENOM and GENAISSANCE returns the
             MassARRAY Products as directed, at SEQUENOM's expense or (2) to
             repair (and recalibrate as necessitated by repair) the MassARRAY
             Products in whole or in part. MassARRAY Products may not be
             returned to SEQUENOM under any circumstances without SEQUENOM's
             prior authorization. Except as provided in Article 12, SEQUENOM
             shall not be liable, to any extent whatsoever, for any damages
             resulting from or arising out of the use or performance of the
             MassARRAY Products provided under this Agreement, regardless of
             foreseeability or the form of the cause of action,

                                       18
<PAGE>

                                 CONFIDENTIAL

              whether in contract, breach of warranty, tort (including
              negligence, strict liability, or otherwise), and including but not
              limited to damages resulting from loss of data, loss of
              anticipated profits or revenue, or any special, direct, indirect,
              incidental or consequential damages.

     10.3.2  The limited warranty set forth in section 10.3 states GENAISSANCE's
             sole and exclusive remedy and SEQUENOM's sole and exclusive
             responsibility with respect to any alleged breach of this limited
             warranty. Except as provided in section 10.3, the MassARRAY
             Products are provided without warranty of any kind or nature.
             SEQUENOM does not warrant, guarantee, or make any representations
             regarding the use or the results of the use, of the MassARRAY
             Products in terms of correctness, accuracy, reliability, or
             otherwise. GENAISSANCE assumes the entire risk as to the results
             and performance of the MassARRAY Products. The foregoing warranty
             is exclusive and is made in lieu of and to the exclusion of any
             other warranties, whether oral or written, express or implied,
             direct, indirect, by estoppel or otherwise, or created by the
             Uniform Commercial Code or the usage in the industry or the course
             of dealings of the parties, as to any matter whatsoever, including
             but not limited to those concerning merchantability or fitness for
             a particular purpose.

                         ARTICLE 11.  CONFIDENTIALITY

11.1 For the purpose of this Agreement, Confidential Information means all
     information, data, and material, labeled or otherwise designated or
     identified as confidential by SEQUENOM or by GENAISSANCE or their
     Affiliates.

     11.1.1  All information relating to SEQUENOM's MassARRAY Products including
             but not limited to, price, quantity, discount, delivery schedule,
             improvements, standard operating procedure documents, operation
             manuals, schematics, design specifications, manufacturing and
             related specifications, is hereby designated as SEQUENOM's
             Confidential Information. SEQUENOM agrees that it will, in writing,
             clearly identify as confidential, any and all information that it
             provides to GENAISSANCE that it considers to be the Confidential
             Information of SEQUENOM.

     11.1.2  Any and all data generated by GENAISSANCE's use of MassARRAY
             Products is hereby designated as GENAISSANCE's Confidential
             Information. All information that GENAISSANCE has received from a
             third party under an obligation of confidentiality to the third
             party is also hereby designated as GENAISSANCE's Confidential
             Information. GENAISSANCE agrees that it will, in writing, clearly
             identify as confidential, any and all SNPs and any other
             information that it provides to SEQUENOM and that it considers to
             be the Confidential Information of GENAISSANCE.

11.3 Each party may use the other party's Confidential Information only for the
     purpose of performing under this Agreement. For the avoidance of doubt, the
     parties agree that

                                       19
<PAGE>

      ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
      CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                 CONFIDENTIAL

     neither party shall include in its database of gene variation any
     information relating to a SNP that is the Confidential Information of the
     other party unless such information is derived independently of such
     Confidential Information.  All Confidential Information remains the sole
     property of the disclosing party.  Upon termination or expiration of this
     Agreement, all materials and all copies of all materials containing
     Confidential Information, including but not limited to papers, books, logs,
     correspondence and records, in any form, whether written, typed,
     electronic, videotape, audiotape, etc., shall be returned to the disclosing
     party within thirty (30) days of the termination or expiration of this
     Agreement, except that each party may retain a single copy of the other
     party's Confidential Information solely for the purpose of ensuring
     compliance under this Agreement and GENAISSANCE may retain and use a copy
     of Genolyzer(TM) Software for a period of ************** after termination
     of this Agreement solely for the purpose of providing genotyping data that
     has been created under this Agreement while this Agreement was in effect,
     to a regulatory agency or to a HAP(TM) Marker Genotyping Collaborator.
     GENAISSANCE shall have the right to capture in any and all digital forms
     any type of data generated from its use of MassARRAY Products and
     Genolyzer(TM) Software during the term of this Agreement.

11.4 Except as expressly provided herein, SEQUENOM and GENAISSANCE Affiliates,
     officers, employees, agents, consultants, and authorized representatives
     (a) shall hold in strict confidence all Confidential Information from the
     other party or any of its Affiliates, officers, employees, agents or
     representatives and (b) shall not distribute, disclose or disseminate such
     Confidential Information to any third party without the prior written
     approval of the other party (that is, the original disclosing party),
     provided, however, that such approval will not be unreasonably withheld
     where the receiving party reasonably believes that disclosure of the other
     party's Confidential Information is reasonably necessary to obtain patents,
     authorization to conduct clinical trials, or regulatory approval, and
     provided that GENAISSANCE may, at its sole option and discretion, disclose
     to its HAP(TM) Marker Genotyping Collaborators only that SEQUENOM
     Confidential Information directly relating to MassARRAY Assays for Non-
     proprietary SNPs on condition that such Collaborators agree in writing to
     keep such information confidential to the same extent as GENAISSANCE is
     required to keep the Confidential Information confidential.

11.5 For purposes of this section, information will not be considered to be
     Confidential Information of a party if the information:

     (i)  was lawfully in the receiving party's possession prior to disclosure
          under this Agreement and was not acquired directly or indirectly from
          the disclosing party; or

     (ii) was, at the date of disclosure by the disclosing party, public
          knowledge; or subsequently becomes public knowledge other than through
          the failure of the receiving party to comply with its obligations of
          confidentiality under the terms of this Agreement; or

                                       20
<PAGE>

                                 CONFIDENTIAL

     (iii) was or is acquired by the receiving party from any third party
           lawfully having possession of such information and who is not under
           an obligation of confidentiality to the disclosing party; or

     (iv)  was or becomes independently known by the receiving party without
           utilizing information provided by the disclosing party and wherein
           such independent knowledge is supported in contemporaneously written
           and dated documentation of the receiving party; or

     (v)   is required to be disclosed, retained, or maintained by either party,
           or by a HAP(TM) Marker Genotyping Collaborator, by applicable law or
           regulation or under the rules of any regulatory or governmental
           authority, provided however that each party shall immediately notify
           the other party in writing of such required disclosure and must
           provide such notice at least thirty (30) days prior to the date when
           disclosure is proposed to take place, and provided that the party or
           third party required to make disclosure shall use its best efforts to
           secure confidential treatment of any such information required to be
           disclosed.

11.6 The parties hereto understand and agree that remedies at law may be
     inadequate to protect against any breach of any of the provisions of this
     Article 11 by either party or their employees, agents, officers or
     directors or any other person acting in concert with it or on its behalf.
     Accordingly, each party shall be entitled to the granting of injunctive
     relief by a court of competent jurisdiction against any action that
     constitutes any such breach of this Article 11.

11.7 Either party may publish or present data and/or results generated under
     this Agreement, provided that, the proposed disclosure shall be subject to
     the prior review by the other party solely to determine (i) whether the
     proposed disclosure contains the Confidential Information of the other
     party, (ii) whether the information contained in the proposed disclosure
     should be the subject of a patent application prior to such disclosure or
     (iii) whether the disclosure would be adverse to the business interests of
     the other party. Each party shall provide the other party with the
     opportunity to review any proposed abstract, manuscript or presentation by
     delivering a copy thereof to the other party no less than thirty (30) days
     before its intended submission for publication or presentation. The other
     party shall have thirty (30) days from its receipt of any such abstract,
     manuscript or presentation in which to notify the party in writing of any
     specific objections to the disclosure. In the event a party objects to the
     disclosure, the other party agrees not to submit the publication or make
     the presentation containing the objected-to information until the party is
     given a reasonable additional period of time (not to exceed an additional
     thirty (30) days) to seek patent protection for any material in the
     disclosure which it believes is patentable or, in the case of Confidential
     Information, to allow the party to delete any Confidential Information of
     the other party from the proposed disclosure. Each party agrees to delete
     from the proposed disclosure any Confidential Information or information
     that would be adverse to the business interests of the other party upon
     request.

                                       21
<PAGE>

                                 CONFIDENTIAL

11.8 Except as provided in section 11.3, the provisions of Article 11 shall
     survive any termination or expiration of this Agreement and continue in
     force for a period of ten (10) years following the effective date of any
     such termination or expiration.

                          ARTICLE 12. INDEMNIFICATION

12.1 In the event of an accusation, claim or lawsuit brought by a third party
     for infringement of a patent, copyright, or other proprietary right of a
     third party, based upon GENAISSANCE's use of the MassARRAY Products and
     performance of MassEXTEND(TM) Methods and Processes in accordance with the
     product information, notices, and instructions for use provided therewith,
     SEQUENOM shall use its best efforts to procure for GENAISSANCE the right to
     continue such use, or if unable to procure such continued use, then
     SEQUENOM shall use its best efforts to provide a substitute, non-infringing
     product which provides substantially the same results.  In any event,
     SEQUENOM shall defend the accusation, claim or lawsuit and indemnify
     GENAISSANCE for any damages which may be awarded, provided that GENAISSANCE
     (1) provide prompt written notice of the accusation, claim or lawsuit to
     SEQUENOM; (2) authorize and provide SEQUENOM with complete control of the
     defense of the accusation, claim or lawsuit and any and all settlements,
     negotiations, compromises, and discussions thereof; (3) cooperate fully
     with SEQUENOM and provide SEQUENOM with such reasonable assistance, as
     SEQUENOM may request in the defense of such accusation, claim or lawsuit;
     and (4) make no statements or admissions directly or indirectly related to
     the MassARRAY Products or intellectual property related to the accusation,
     claim, or lawsuit, or the merits or lack of merit of any accusation, claim,
     or lawsuit, without the express written permission of SEQUENOM.  Nothing in
     this provision shall be construed to prevent GENAISSANCE from participating
     in (but not controlling) the defense of any such action, with its counsel
     and at its own expense.

12.2 GENAISSANCE IS HEREBY PUT ON NOTICE THAT SEQUENOM'S MASSARRAY PRODUCTS
     HAVE NOT BEEN SUBJECTED TO REGULATORY REVIEW OR APPROVED BY THE FEDERAL
     FOOD AND DRUG ADMINISTRATION OR ANY OTHER UNITED STATES GOVERNMENTAL AGENCY
     OR ENTITY, UNDER ANY STATUTE, FOR ANY PURPOSE, RESEARCH, COMMERCIAL, OR
     OTHERWISE.

                              ARTICLE 13. NOTICES

13.1 All notices and requests required or authorized hereunder shall be given in
     writing either by personal delivery; by registered or certified mail,
     return receipt requested; or by confirmed facsimile followed by first class
     mail or express delivery. Such notice shall be deemed to have been given
     upon such date that it is so personally delivered; the date three (3) days
     after it is deposited in the mail; or the date the same is received by the
     receiving party's fax machine, irrespective of the date appearing therein.

                                       22
<PAGE>

                                 CONFIDENTIAL

     If to GENAISSANCE:                      If to SEQUENOM:
     GENAISSANCE PHARMACEUTICALS, Inc.       SEQUENOM, Inc.
     Attention: Gerald F. Vovis, Ph.D.       Attention: President and CEO
     Five Science Park                       11555 Sorrento Valley Road
     New Haven, CT 06511                     San Diego, CA 92121-1331
     Tel: (203) 773-1450                     Tel: (858) 350-0345
     Fax: (203) 562-9377                     Fax: (858) 350-0344

     and a copy to:                          and a copy to:

     GENAISSANCE PHARMACEUTICALS, Inc.       SEQUENOM, Inc.
     Attention: Melodie W. Henderson         Attention: Corporate Counsel
     Five Science Park                       11555 Sorrento Valley Road
     New Haven, CT 06511                     San Diego, CA 92121-1331
     Tel: (203) 773-1450                     Tel: (858) 350-0345
     Fax: (203) 562-9377                     Fax: (858) 350-0344

                             ARTICLE 14.  GENERAL

14.1 Force Majeure.  Except with respect to the payment of money, neither party
     --------------
     shall be liable for any failure or delay in its performance under this
     Agreement due to causes, including, but not limited to, acts of God, acts
     of civil or military authority, fires, epidemics, floods, earthquakes,
     riots, wars, sabotage, labor shortages or disputes, and governmental
     actions, which are beyond its reasonable control; provided that the delayed
     party: (i) gives the other party written notice of such cause and (ii) uses
     its reasonable efforts to correct such failure or delay in its performance.
     The delayed party's time for performance or cure under this section 14.1
     shall be extended for a period equal to the duration of the cause.

14.2 Relationship of Parties.  The parties to this Agreement are independent
     ------------------------
     contractors.  Neither party nor their respective Affiliates, employees,
     consultants, contractors or agents, are Affiliates, agents, employees,
     joint ventures of the other, nor do they have any authority to bind the
     other by contract or otherwise to any obligation.  Neither party will
     represent anything to the contrary, either expressly, implicitly, by
     appearance or otherwise.

14.3 Assignment.  The parties may not assign this Agreement in whole or in part
     -----------
     without the consent of the other, except if such assignment occurs in
     connection with the sale or transfer of all or substantially all of the
     assets of a party to which the subject matter of this Agreement pertains.
     Notwithstanding the foregoing, any party may assign its rights (but not its
     obligations) pursuant to this Agreement in whole or in part to an Affiliate
     of such party.

14.4 Successors in Interest. Subject to section 14.3, the rights and liabilities
     -----------------------
     of the parties hereto will bind and inure to the benefit of their
     respective successors, executors and administrators, as the case may be.

                                       23
<PAGE>

                                 CONFIDENTIAL

14.5  Applicable Law.  This Agreement shall be governed by and construed in
      ---------------
      accordance with the laws of Delaware, U.S.A., exclusive of its conflicts
      of law rules. Any litigation between the parties relating to this
      Agreement shall take place in Delaware and the parties consent to the
      personal jurisdiction of and venue in the state and federal courts within
      Delaware.

14.6  Dispute Resolution.  The parties hereby agree that they will attempt in
      -------------------
      good faith to resolve any controversy or claim arising out of or relating
      to this Agreement promptly by negotiations. If a controversy or claim
      should arise hereunder, the matter shall be referred to an individual
      designated by the Chief Executive Officer (or the equivalent position) of
      GENAISSANCE and an individual designated by the President (or the
      equivalent position) of SEQUENOM (the "Representatives"). If the matter
      has not been resolved within thirty (30) days of the first meeting of the
      Representatives of the parties (which period may be extended by mutual
      agreement) concerning such matter, either party may bring suit in an
      appropriate state or federal court. Nothing herein shall preclude the
      parties from agreeing to binding arbitration at a location and under rules
      agreed to by each party.

14.7  Severability.  If for any reason a court of competent jurisdiction finds
      -------------
      any provision of this Agreement, or portion thereof, to be unenforceable,
      that provision of the Agreement shall be enforced to the maximum extent
      permissible so as to effect the intent of the parties, and the remainder
      of this Agreement shall continue in full force and effect.

14.8  No Waiver.  Failure by either party to enforce any term, provision, or
      ----------
      condition of this Agreement shall not be deemed a waiver of future
      enforcement of that or any other term, provision, or condition. No waiver
      of a term, provision, or condition of this Agreement in any one or more
      instances, whether by context, implication, express, or otherwise, shall
      be construed to be a further or continuing waiver of such term, provision,
      or condition.

14.9  Counterparts.  This Agreement may be executed in one or more counterparts,
      -------------
      each of which will be deemed an original, but all of which will constitute
      but one and the same instrument.

14.10 Facsimile Copies.  For purposes of this Agreement, a signed facsimile
      -----------------
      copy shall have the same force and effect as an original signed Agreement.

14.11 Complete Agreement.  This Agreement, including all Appendices,
      -------------------
      constitutes the entire agreement between the parties with respect to the
      subject matter hereof, and supersedes and replaces all prior or
      contemporaneous understandings or agreements, written or oral, regarding
      such subject matter. No amendment to or modification of this Agreement
      shall be binding unless in writing and signed by a duly authorized
      representative of both parties.

                                       24
<PAGE>

                                 CONFIDENTIAL

14.12  Third Party Beneficiaries.  Except as specifically set forth herein, no
       --------------------------
       third party beneficiary rights are conferred or are intended to be
       conferred by this Agreement.

14.13  Headings.  Headings in this Agreement are for convenience only, and shall
       ---------
       not be used to and shall not affect the meaning or interpretation of this
       Agreement.

14.14  Construction.  This Agreement shall not be strictly construed against any
       -------------
       party hereto, regardless of which party, or how much a party, contributed
       to the drafting of the Agreement.

14.15  Public Announcements. Any announcements or similar publicity with respect
       ---------------------
       to the execution of this Agreement shall be agreed upon among the parties
       in advance of such announcement. The parties understand that this
       Agreement is likely to be of significant interest to investors, analysts
       and others, and that any of the parties therefore may make such public
       announcements with respect thereto, provided that the disclosing party
       has complied with the conditions of this section 14.15. The parties agree
       that any such announcement will not contain confidential business or
       technical information and, if disclosure of confidential business or
       technical information is required by law or regulation, the disclosing
       party will use its best efforts to minimize such disclosure and obtain
       confidential treatment for any such information which is disclosed to a
       governmental agency or group. Each party agrees to provide to the other
       party a copy of any public announcement as soon as reasonably practicable
       under the circumstances prior to its scheduled release. Each party shall
       provide the other with an advance copy of any press release at least ten
       (10) business days prior to the scheduled disclosure. Each party shall
       have the right to expeditiously review and recommend changes to any
       announcement regarding this Agreement or the subject matter of this
       Agreement. Except as otherwise required by law, the party whose press
       release has been reviewed shall remove any information the reviewing
       party reasonably deems to be inappropriate for disclosure.

14.16  Conflicts.  In the event that a conflict arises between this Agreement
       ----------
       and any work order, purchase order, billing statement, or invoice related
       to the purchase of and right to use MassARRAY(TM) Products, this
       Agreement will govern and the conflicting terms, provisions, and
       conditions of any such other documents shall be deemed nonexistent, and
       shall not be binding upon either party.

                                       25
<PAGE>

                                 CONFIDENTIAL

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first indicated above.

GENAISSANCE                                  SEQUENOM, Inc.
PHARMACEUTICALS, Inc.

By:    /s/ Gerald F. Vovis                   By:    /s/ Toni Schuh
   ----------------------------------           -------------------------------

Name:  Gerald F. Vovis, Ph.D.                Name:  Toni Schuh

Title: Senior Vice-President of Genomics     Title: Executive Vice-President

Date:           3 May 2000                   Date:        4 May 2000
     --------------------------------             -----------------------------

                                       26
<PAGE>

                                                                    CONFIDENTIAL

                                  APPENDIX A

                             MassARRAY(TM) System

High-speed SpectroSCAN(TM) array mass spectrometer for separation, detection and
characterization of the analyte molecules from a miniaturized array; configured
with:

     .    a 10-chip SCOUT MALDI target
     .    high precision x/y positioning stage (4 m/step)
     .    low maintenance N\\2\\ UV laser (10Hz) for sample ionization
     .    gridless pulsed ion extraction
     .    125 cm linear TOF analyzer with gated detector
     .    fuzzy logic feedback control
     .    2 GHz digitizer for high-accuracy data acquisition
     .    Workstation, post processing software

SpectroJET(TM), 4-Channel, v1.1, dispenser for nanoliter sample transfer,
equipped with:

     .    SPIP Micropump with 800 nl chamber volume
     .    droplet volume range of 0.5-2 nl
     .    CV(less than)2% dispensing precision of the pump
     .    0.1 mm precision of x/y positioning stage
     .    maximum speed of 41.9 cm/sec
     .    PC, controller software

Automated Multipipettor including:

     .    96-channel automated pipettor
     .    pipetting volume range of 2-200  l
     .    magnetic lifter for bead separation
     .    six position workdeck
     .    PC, controller software

Biomass Workstation for data management and interpretation

     .    Workstation (hardware)
     .    Genolyzer/(TM)/ software
     .    Oracle database

                                      A-1
<PAGE>

                                                                    CONFIDENTIAL

                                  APPENDIX B

                               MassARRAY(TM) Kit

<TABLE>
<CAPTION>
----------------------------------------------------------------------------------------------------------
 Kit Package         Storage                    Components                  Quantity        Dilutions
                      Temp.
----------------------------------------------------------------------------------------------------------
<S>               <C>                 <C>                                   <C>          <C>
Reaction          2-8(degrees) C      Beads                                   16 mL            none
Components B                          Binding Buffer                          60 mL      1:3 & undiluted
                                      Denaturation Solution                   60 mL            1:10
                                      Wash & Conditioning Buffer            2 x 60 mL          1:10
                                      Recovery Solution                       60 mL            1:10

----------------------------------------------------------------------------------------------------------

SpectroCHIP(TM)   15-25(degrees) C    384-D SpectroCHIP(TM) (96-D             10               n / a
Pack                                  Spectro CHIP(TM) will be supplied
                                      until 384-D available)
----------------------------------------------------------------------------------------------------------
</TABLE>

                                      B-1
<PAGE>

                                                                    CONFIDENTIAL

                                kit composition
<TABLE>
<CAPTION>
    Inventory items       Basic Kit        Kit Composition    Genomics    R&D
    ---------------       ---------        ---------------    --------    ---
------------------------------------------------------------------------------------------------------------
                               Basic Kit Composition (MFGLST00002, R00)
------------------------------------------------------------------------------------------------------------
Components        Quantity                  Formulation                   Shipping        Storage       Co
                                                                         Conditions     Conditions
------------------------------------------------------------------------------------------------------------
<S>                <C>        <C>                                        <C>           <C>             <C>
Probe Enzyme       3840 U     Thermosequenase (32U/ul)                      Cold       Frozen(-20C)    10u
                                                                                                       20%
                                                                                                       due
                                                                                                       diffi
------------------------------------------------------------------------------------------------------------
PROBE Mix 1        2.0 ml     10X Buffer, 0.5mM ddATP, 0.5mM ddCTP,         Cold       Frozen (-20C)
                              0.5 mM dGTP, 0.5mM dTTP
------------------------------------------------------------------------------------------------------------
PROBE Mix 2        2.0 ml     10X Buffer, 0.5mM ddATP, 0.5mM ddGTP,         Cold       Frozen (-20C)
                              0.5mM dCTP, 0.5mM dTTP
------------------------------------------------------------------------------------------------------------
PROBE Mix 3        2.0 ml     10X Buffer, 0.5mM ddATP, 0.5mM ddTTP,         Cold       Frozen (-20C)
                              0.5mM dCTP, 0.5mM dGTP
------------------------------------------------------------------------------------------------------------
PROBE Mix 4        2.0 ml     10X Buffer, 0.5mM ddCTP, 0.5mM ddGTP,         Cold       Frozen (-20C)
                              0.5mM dATP, 0.5mM dTTP
------------------------------------------------------------------------------------------------------------
PROBE Mix 5        2.0 ml     10X Buffer, 0.5mM ddCTP, 0.5mM ddTTP,         Cold       Frozen (-20C)
                              0.5mM dATP, 0.5mM dGTP
------------------------------------------------------------------------------------------------------------
PROBE Mix 6        2.0 ml     10X Buffer, 0.5mM ddGTP, 0.5mM ddTTP,         Cold       Frozen (-20C)
                              0.5mM dATP, 0.5mM dCTP
------------------------------------------------------------------------------------------------------------
SpectroChips          10      TF1, 96well, 0.8 um pad height              Room Temp    Room Temp
------------------------------------------------------------------------------------------------------------
Matrix             pre-       70/10/10 3-HPA, Acetonitrile, Ammonium         n/a       n/a
                 applied      Citrate
------------------------------------------------------------------------------------------------------------
Magnetic Beads     16 ml      Dynal Beads, d=2.8um                        Room Temp    Cold (2-8C)
------------------------------------------------------------------------------------------------------------
Binding Buffer     60 ml      3M NaC1, 15mM Tris-HCI pH7.5, 1.5mM         Room Temp    Cold (2-8C)
                              EDTA (3X)
------------------------------------------------------------------------------------------------------------
Denaturation       60 ml      1N NaOH (10x concentrate)                   Room Temp    Cold (2-8C)
Buffer
------------------------------------------------------------------------------------------------------------
Wash &            2 x 60 ml   100mM Tris-HCI pH=8.0 (10x concentrate)     Room Temp    Cold (2-8C)
Conditioning
Buffer
------------------------------------------------------------------------------------------------------------
Recovery           60 ml      0.5M NH40H (10x concentrate)                Room Temp    Cold (2-8C)
Solution
------------------------------------------------------------------------------------------------------------
Positive           25 ul      25uM PCR Primer PC-F, 10uM PCR Primer         Cold       Frozen (-20C)   25r
Control - PCR                 PC-R-bio, 1X TE Buffer
Primers
------------------------------------------------------------------------------------------------------------
Positive           50 ul      10uM PROBE Primer PC-P, 1X TE Buffer          Cold       Frozen (-20C)   25
Control -                                                                                              20p
PROBE Primer
------------------------------------------------------------------------------------------------------------
Calibrant          125 ul     0.3uM Oligo standard 17, 1.0uM Oligo          Cold       Frozen (-20C)   25
                              standard 28, 1.0uM Oligo standard 33                                     5ul/
------------------------------------------------------------------------------------------------------------
</TABLE>

                                      B-2
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
                 CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                                                    CONFIDENTIAL

                                  APPENDIX C

                                     *****

                                      C-1
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
                 CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                                                    CONFIDENTIAL

                                  APPENDIX D

                                     *****

                                      D-1
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
                 CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                                                    CONFIDENTIAL

                                  APPENDIX E

                                     *****

                                      E-1
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
                 CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                                                    CONFIDENTIAL

                                  APPENDIX F

                                     *****

                                      F-1
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
                 CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                                                    CONFIDENTIAL

                                  APPENDIX G

                                                      PURCHASE ORDER NO.   15975
                                                                           -----

SHIP TO:
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511
(203) 773-1450

BILL TO:
Finova Capital Corporation
Attn: Barbara Sullivan
10 Waterside Drive
Farmington, CT 06032-3065
860-674-7503
                                                          Req. By: K. Nandabalan
Date:       1/26/00                                    Approved By:_____________
       -----------------------
To:    Sequenom
       -----------------------
Phone:  (978) 371-9830 ext 17      Daniel Little, Ph.D.
       -----------------------
Fax:    (978) 371-9644
       -----------------------

<TABLE>
<CAPTION>
   Acct #        Job Desc.       Qty.      Part #                   Description                 Unit Price      Total
------------------------------------------------------------------------------------------------------------------------
                                  *        SYSTEM     MassArray System                          **********     ********
------------------------------------------------------------------------------------------------------------------------
<S>           <C>              <C>       <C>          <C>                                      <C>            <C>
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                      ANY UPGRADES TO ANY OF THE COMPONENTS                         0.00
--------------------------------------------------    ARE TO BE MADE ONSITE BY SEQUENOM AS    --------------------------
                                                      SOON AS THESE UPGRADES ARE AVAILABLE                          0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                         TOTAL                    ******
------------------------------------------------------------------------------------------------------------------------

Reference/Order No.                                                                            Date: ___________________
                                                                                               With: ___________________
                                                                                  Expected Delivery: ___________________
------------------------------------------------------------------------------------------------------------------------
</TABLE>

                                      G-1
<PAGE>

                                                                    CONFIDENTIAL

                             [SEQUENOM LETTERHEAD]

                                                                January 24, 2000

Dr. Krishnan Nandabalan
Genaissance Pharmaceuticals
Five Science Park
New Haven, CT 06511
(203) 773-1450 x3045

Dear Krishnan,

     Please find to follow a proposal for a MassArray(TM) system for initial
experiments and assay validation at Genaissance. If the proposal is accepted by
the end of January we can guarantee the requested accelerated (4 weeks from
order placement) delivery.

     We have included in this quotation the Spectroscan(TM) Biflex (developed
with our partner Bruker Daltonics) as the mass spectrometer. While we are
progressing on the development and validation of the Spectroscan Voyager
(developed with our partner Perkin Elmer), we cannot offer this as part of a
validated system within the next month. We will of course introduce you to both
mass spectrometers preceding the establishment of the multi-system core
genotyping facility at Genaissance later this year. Likewise, we will in this
timeframe give demonstration of the high-throughput sample processing station
capable of processing more than 25 384-well microtiter plates per day, which is
a product of our collaboration with the lab automation division of Beckman
Instruments.

     Please do not hesitate to contact me by phone, fax, or email if there are
any questions.

                                              Best regards,

                                              /s/ Daniel P. Little

                                              Daniel P. Little, Ph.D.
                                              Director, East Coast Operations

                                      G-2
<PAGE>

                                                                    CONFIDENTIAL

                                   Proposal

                                By and between

                                 Sequenom Inc.
          1-555 Sorrento Valley Road, San Diego, CA  92121-1331, USA,
                     -Hereinafter referred to as SEQUENOM-

                                      and

                                  Genaissance
                   -Hereinafter referred to as GENAISSANCE-

PROPOSAL

SEQUENOM is pleased to provide the GENAISSANCE with a non-binding proposal for
a MassArray(TM) System ("SYSTEM") which incorporates the following components:

-    High-speed SpectroSCAN Biflex array mass spectrometer for separation,
     detection and characterization of the analyte molecules from a miniaturized
     array; configured with:
          .  a 10-chip MALDI target
          .  high precision x/y positioning stage (4 um/step)
          .  low maintenance N\\2\\ UV laser (10Hz) for sample ionization
          .  High speed digitizer for high-accuracy data acquisition
          .  Data acquisition workstation

-    SpectroJET, 4-Channel, v1.1, dispenser for nanoliter sample transfer (from
     microtiter plate to Spectrochip); equipped with:
          .  Micropump
          .  droplet volume range of 0.5-2 nl
          .  CV *2% dispensing precision of the pump
          .  0.1 mm precision of x/y positioning stage
          .  PC, controller software

-    SpectroPREP Automated Multipipettor including:
          .  96-channel automated pipettor
          .  pipetting volume range of 2-200 u
          .  magnetic lifter for solid support (bead) manipulation
          .  six position workdeck
          .  PC, controller software

* Less than
                                      G-3
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
                 CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                                                    CONFIDENTIAL

-    Data management and interpretation tools

          .  Workstation (hardware)
          .  SpectroTYPER software
          .  Oracle database

TERMS AND CONDITIONS

1. Price for SYSTEM $********** (************************************ US
   Dollars).
2. This is a non-binding quotation for the products and services printed above.
3. Proposal pricing valid for sixty (60) days after issue.
4. Upon acceptance of this Proposal, both parties will enter into an Agreement
   outlining the terms and conditions as mutually agreed upon.
5. Terms of the strategic alliance agreement under discussion between
   Genaissance and Sequenom will take precedence over those outlined here, upon
   singing of said strategic alliance agreement.
6. All product and software licenses are valid only when used with authorized
   SEQUENOM consumables.
7. Delivery Date:  4-weeks after the order is placed; order must be placed by
   January 31, 2000 to guarantee the accelerated delivery schedule.  Valid for
   this proposal only.

SEQUENOM warrants that the SYSTEM conforms to specifications and performs as
specified for a period of six (6) months beginning on the date of the first test
result provided by SYSTEM after it is installed at GENAISSANCE by SEQUENOM.
Genaissance may, at its discretion, purchase an annual service and maintenance
agreement from SEQUENOM. The service and maintenance price will depend on the
system configuration GENAISSANCE purchases.

                                      G-4
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
                 CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

Genaissance Pharmaceuticals
Confidential and Proprietary

                                  APPENDIX H

                                     *****

                                      H-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}]]